US20070189982A1 - Diagnostics and treatments of Periodontal disease - Google Patents
Diagnostics and treatments of Periodontal disease Download PDFInfo
- Publication number
- US20070189982A1 US20070189982A1 US11/654,512 US65451207A US2007189982A1 US 20070189982 A1 US20070189982 A1 US 20070189982A1 US 65451207 A US65451207 A US 65451207A US 2007189982 A1 US2007189982 A1 US 2007189982A1
- Authority
- US
- United States
- Prior art keywords
- prtr
- prtk
- complex
- gingivalis
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000028169 periodontal disease Diseases 0.000 title abstract description 8
- 238000011282 treatment Methods 0.000 title abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 113
- 241000605862 Porphyromonas gingivalis Species 0.000 claims abstract description 87
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 79
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000004472 Lysine Substances 0.000 claims abstract description 23
- 239000004475 Arginine Substances 0.000 claims abstract description 17
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 17
- 108010059378 Endopeptidases Proteins 0.000 claims abstract description 9
- 102000005593 Endopeptidases Human genes 0.000 claims abstract description 9
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims abstract description 8
- 229940066758 endopeptidases Drugs 0.000 claims abstract description 5
- 230000000890 antigenic effect Effects 0.000 claims abstract description 4
- 230000005875 antibody response Effects 0.000 claims abstract description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 239000002324 mouth wash Substances 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 239000000551 dentifrice Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229940051866 mouthwash Drugs 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 abstract description 75
- 238000001514 detection method Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 2
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 68
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 55
- 239000000872 buffer Substances 0.000 description 46
- 230000002797 proteolythic effect Effects 0.000 description 37
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 35
- 229960005486 vaccine Drugs 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 34
- 102000053602 DNA Human genes 0.000 description 34
- 239000013598 vector Substances 0.000 description 29
- 241000894006 Bacteria Species 0.000 description 28
- 239000011780 sodium chloride Substances 0.000 description 28
- 229920002684 Sepharose Polymers 0.000 description 26
- 239000002671 adjuvant Substances 0.000 description 26
- 239000000463 material Substances 0.000 description 26
- 230000003024 amidolytic effect Effects 0.000 description 23
- 229960003646 lysine Drugs 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000002523 gelfiltration Methods 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 19
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 102000035195 Peptidases Human genes 0.000 description 17
- 108091005804 Peptidases Proteins 0.000 description 17
- 239000000499 gel Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 229960003121 arginine Drugs 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 239000000606 toothpaste Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 13
- 101100342162 Porphyromonas gingivalis kgp gene Proteins 0.000 description 13
- -1 adhesins Substances 0.000 description 13
- 229940034610 toothpaste Drugs 0.000 description 13
- 241000335876 Porphyromonas gingivalis W50 Species 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 238000005349 anion exchange Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000002163 immunogen Effects 0.000 description 12
- 230000003902 lesion Effects 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 210000000214 mouth Anatomy 0.000 description 12
- 235000019833 protease Nutrition 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 101001027496 Porphyromonas gingivalis Lys-gingipain W83 Proteins 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 10
- 230000001810 trypsinlike Effects 0.000 description 10
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 101800001509 Large capsid protein Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 201000001245 periodontitis Diseases 0.000 description 9
- 238000005498 polishing Methods 0.000 description 9
- 239000000600 sorbitol Substances 0.000 description 9
- 235000010356 sorbitol Nutrition 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 210000004201 immune sera Anatomy 0.000 description 8
- 229940042743 immune sera Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 101100298851 Aspergillus oryzae (strain ATCC 42149 / RIB 40) prtT gene Proteins 0.000 description 7
- 241000283073 Equus caballus Species 0.000 description 7
- 101100298845 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) prtR gene Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 229960001212 bacterial vaccine Drugs 0.000 description 7
- 239000005018 casein Substances 0.000 description 7
- 101150023726 degR gene Proteins 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 125000001288 lysyl group Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 5
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 108010041102 azocasein Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 5
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000185 hemagglutinin Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108091020100 Gingipain Cysteine Endopeptidases Proteins 0.000 description 4
- 239000012901 Milli-Q water Substances 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 108010076039 Polyproteins Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 101150065453 prtR gene Proteins 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229960004854 viral vaccine Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 108010001682 Dextranase Proteins 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108050001049 Extracellular proteins Proteins 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 208000005888 Periodontal Pocket Diseases 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 description 3
- 101710097834 Thiol protease Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 208000034391 chronic adult periodontitis Diseases 0.000 description 3
- 208000001277 chronic periodontitis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 3
- 235000011837 pasties Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 108010042889 Inulosucrase Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100027612 Kallikrein-11 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101000723939 Mus musculus Transcription factor HIVEP3 Proteins 0.000 description 2
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 241000656145 Thyrsites atun Species 0.000 description 2
- 101710152431 Trypsin-like protease Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003366 colagenolytic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940094522 laponite Drugs 0.000 description 2
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000005341 metaphosphate group Chemical group 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical class CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 description 1
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical class CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 101710144734 48 kDa protein Proteins 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101001057129 Bacillus cereus Enterotoxin Proteins 0.000 description 1
- 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
- 102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 240000000896 Dyera costulata Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N Li2O Inorganic materials [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 101710151833 Movement protein TGBp3 Proteins 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- 101000700655 Mycobacterium leprae (strain TN) Serine-rich antigen Proteins 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- XCOJIVIDDFTHGB-UEUZTHOGSA-N Perillartine Chemical compound CC(=C)[C@H]1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-UEUZTHOGSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 102100022135 S-arrestin Human genes 0.000 description 1
- 101710117586 S-arrestin Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 229920006387 Vinylite Polymers 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000007474 bm medium Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 101150039352 can gene Proteins 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000012532 cell-free culture fluid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229910002026 crystalline silica Inorganic materials 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- XUCJHNOBJLKZNU-UHFFFAOYSA-M dilithium;hydroxide Chemical compound [Li+].[Li+].[OH-] XUCJHNOBJLKZNU-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001759 immunoprophylactic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 101150073640 ompF gene Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- AZJYLVAUMGUUBL-UHFFFAOYSA-A u1qj22mc8e Chemical group [F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O=[Si]=O.O=[Si]=O.O=[Si]=O.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 AZJYLVAUMGUUBL-UHFFFAOYSA-A 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56955—Bacteria involved in periodontal diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis and in particular a multimeric cell associated protein complex comprising the PrtR and PrtK proteins.
- the invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis.
- Periodontal diseases are bacterial-associated inflammatory diseases of the supporting tissues of the teeth and range from the relatively mild form of gingivitis, the non-specific, reversible inflammation of gingival tissue to the more aggressive forms of periodontitis which are characterised by the destruction of the tooth's supporting structures.
- Periodontitis is associated with a subgingival infection of a consortium of specific Gram-negative bacteria that leads to the destruction of the periodontium and is a major public health problem.
- P. gingivalis As the recovery of this microorganism from adult periodontitis lesions can be up to 50% of the subgingival anaerobically cultivable flora, whereas P.
- gingivalis is rarely recovered, and then in low numbers, from healthy sites.
- a proportional increase in the level of P. gingivalis in subgingival plaque has been associated with an increased severity of periodontitis and eradication of the microorganism from the cultivable subgingival microbial population is accompanied by resolution of the disease.
- the progression of periodontitis lesions in non-human primates has been demonstrated with the subgingival implantation of P. gingivalis.
- P. gingivalis is a black-pigmented, anaerobic, asaccharolytic, proteolytic Gram-negative rod that obtains energy from the metabolism of specific amino acids.
- the microorganism has an absolute growth requirement for iron, preferentially in the form of haeme or its Fe(III) oxidation product haemin and when grown under conditions of excess haemin is highly virulent in experimental animals.
- a number of virulence factors have been implicated in the pathogenicity of P. gingivalis including the capsule, adhesins, cytotoxins and extracellular hydrolytic enzymes.
- proteases have received a great deal of attention for their ability to degrade a broad range of host proteins including structural proteins and others involved in defence.
- the proteins that have been shown to be substrates for P. gingivalis proteolytic activity include collagen types 1 and IV, fibronectin, fibrinogen, laminin, complement and plasma clotting cascade proteins, ⁇ i-antitrypsin, ⁇ macroglobulin, antichymotrypsin, antithrombin III, antiplasmin, cystatin C, IgG and IgA.
- the major proteolytic activities associated with this organism have been defined by substrate specificity and are “trypsin-like”, that is cleavage on the carboxyl side of arginyl and lysyl residues and collagenolytic although other minor activities have been reported.
- P. gingivalis trypsin-like proteolytic activity has been shown to degrade complement, generating biologically active C5a, impair the phagocytic and other functions of neutrophils by modifying surface receptors, and abrogate the clotting potential of fibrinogen prolonging plasma clotting time.
- the trypsin-like proteolytic activity of P. gingivalis also generates Fc fragments from human IgGI stimulating the release of pro-inflammatory cytokines from mononuclear cells and is associated with vascular disruption and enhanced vascular permeation through the activation of the kallikrein-kinin cascade.
- gingivalis spontaneous mutants with reduced trypsin-like activity as well as wild-type cells treated with the trypsin-like protease inhibitor N-?-tosyl-L-lysine chloromethyl ketone are avirulent in animal models. Further, it has been shown that P. gingivalis grown under controlled, haemin-excess conditions expressed more trypsin-like and less collagenolytic activity and were more virulent in mice relative to cells grown under haemin-limited but otherwise identical conditions. The increased expression of the trypsin-like activity by the more virulent P. gingivalis has led to the speculation that the trypsin-like proteolytic activity may be the major determinant for infection or disease. However, the cell-associated trypsin-like proteolytic activities of P. gingivalis have not been characterised to date.
- PrtR-PrtK cell surface complex exhibiting both arginine- and lysine-specific proteolytic activity together with adhesin activity was previously unknown. Furthermore, the new PrtR-PrtK complex of the present invention is expressed on the cell surface, is a major virulence-associated factor and contains unique epitopes not displayed on the individual domains.
- PrtR-PrtK cell surface complex is accordingly of particular interest for diagnostics and neutralisation by passive immunity through oral compositions containing neutralising antibodies and by vaccine development.
- the recombinant bacterium expressing an inactivated PrtR-PrtK is a genetically engineered commensal inhabitant of the oral cavity.
- the present invention consists in a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis, the complex comprising at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain, the complex having a molecular weight of greater than about 200 kDa.
- hesin and “hemagglutinin” may be considered to be synonymous.
- the multimeric protein complex is associated with virulent strains of Porphyronionas gingivalis, preferably has a molecular weight of about 294 to about 323 kDa and is preferably derived from P. gingivalis W50.
- the multimeric protein complex is composed of 9 proteins
- 9 proteins preferably have the following N-terminal sequences: DVYTDHGDLYNTPVRML (SEQ ID NO:1) YTPVEEKQNGRMIVIVAKKYEGD (SEQ ID NO:2) SGQAEIVLEAHDVWNDGSGYQILLDADHDQYGQVIPS (SEQ ID NO:3) DTHFL PQSVWIERTVDLPAGTKYVAFR (SEQ ID NO:4) ANEAKVVLAADNVWGDNTGYQFLLDA (SEQ ID NO:5) ANEAKVVLAADNVWGDNTGYQFLLDA (SEQ ID NO:6) PQSVWIERTVDLPAGTKYVAFR (SEQ ID NO;7) ADFTETFESSTHGEAPAEWTTIDA (SEQ ID NO:8) ADFTETFESSTHGEAPAEWTTIDA (SEQ ID NO:9)
- the 9 proteins are PrtK48, PrtR45, PrtR44, PrtK39, PrtK44, PrtR27, PrtR17, PrtK 15 and PrtR 15 as described herein.
- the purified antigenic complex normally has enzymatic activity it is preferred in a number of uses the thiol endopeptidases are rendered inactive. This may be achieved in a number of ways, for example by oxidation or by mutation. It is presently preferred that the inactivation is by oxidation.
- the multimeric protein complex is encoded by the DNA sequence shown in FIGS. 8B and 9B .
- the present invention consists in a composition for use in eliciting an immune response directed against Porphyromonas gingivalis, the composition comprising an effective amount of the complex of the first aspect of the present invention and a suitable adjuvant and/or acceptable carrier.
- the present invention consists in an antibody preparation comprising antibodies specifically directed against the complex of the first aspect of the present invention.
- the antibodies may be polyclonal antibodies or monoclonal antibodies.
- the present invention consists in a method of treating a subject suffering from Porphyromonas gingivalis infection, the method comprising administering to the subject an amount of the antibody preparation of the third aspect of the present invention effective to at least partially neutralize the PrtR-PrtK complex of Porphyromonas gin givalis.
- the antibody preparation may be administered by any of a number of well known routes, however, it is presently preferred that the preparation is administered orally.
- the present invention consists in a method of reducing the prospect of P. gingivalis infection in an individual and/or severity of disease, the method comprising administering to the individual an amount of the composition of the second aspect of the present invention effective to induce an immune response in the individual directed against P. gingivalis.
- the present invention consists in a recombinant host cell, the host cell being transformed with a DNA sequence(s) encoding PrtR-PrtK operatively linked to control sequences such that under appropriate conditions the host cell expresses PrtR-PrtK.
- the present invention is directed to novel DNA sequences involving PrtR-PrtK constructs and vectors including plasmid DNA, and viral DNA such as human viruses, animal viruses, insect viruses, or bacteriophages which can be used to direct the expression of PrtR-PrtK protein in appropriate host cells from which the expressed protein may be purified.
- Another aspect of the present invention provides methods for molecular cloning of the genes encoding the PrtR-PrtK complex.
- the nucleic acid sequences of the present invention can be used in molecular diagnostic assays for P.
- PrtR-PrtK complex can be used as an immunogen in prophylactic and/or therapeutic vaccine formulations against pathogenic strains of P. gingivalis , whether the immunogen is chemically synthesized, purified from P. gingivalis , or purified from a recombinant expression vector system.
- the genes encoding PrtR-PrtK may be incorporated into a bacterial or viral vaccine comprising recombinant bacteria or virus which is engineered to produce PrtR-PrtK by itself, or in combination with immunogenic epitopes of other pathogenic microorganisms.
- the genes encoding PrtR-PrtK operatively linked to one or more regulatory elements can be introduced directly into humans to express the PrtR-PrtK to elicit a protective immune response.
- a vaccine can also be based upon a recombinant component of a mutated PrtR-PrtK incorporated into an appropriate vector and expressed in a suitable transformed host (eg. E.
- the vaccine can be based on an intra-oral recombinant bacterial vaccine, where the recombinant bacterium expressing an inactivated PrtR-PrtK is a commensal inhabitant of the oral cavity.
- the PrtR-PrtK complex of the invention or component parts thereof are safe and effective antigens for the preparation of a vaccine for the prevention of P. g7//g7v ⁇ //.i-associated periodontal disease.
- the invention therefore provides a range of recombinant products based on the PrtR-PrtK complex.
- the invention also provides antibodies raised against the said PrtR-PrtK complex, herein called anti-PrtR-PrtK antibodies.
- the antibodies may be blended into oral compositions such as toothpaste, mouthwash, toothpowders and liquid dentifrices, mouthwashes, troches, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products and other foodstuffs.
- the invention provides a method of diagnosis for the presence of P. gingivalis characterised by the use of any one or a combination of an antibody, antigen or nucleic acid probe as hereinbefore defined comprising the application of known techniques including for example, enzyme linked immunosorbent assay.
- the invention also provides diagnostic kits comprising antibodies, antigens and/or nucleic acid probes as hereinbefore defined.
- FIG. 1 Anion exchange FPLC of a P. gingivalis W50 sonicate.
- the sonicate in TC buffer containing 50 mM NaCl was applied to a Hiload XK 16/10 Q sepharose column and eluted using a linear gradient from 0-100% buffer B over 90 min at a flow rate of 2 0 ml min ′1 .
- Fractions (6 ml) were assayed for proteolytic and amidolytic activity using azocasein, Bz-L-Arg-/?NA and Z-L-Lys-/?NA
- the amidolytic activity of each 6 ml fraction with Bz-L-Arg-pNA is shown by the histogram.
- FIG. 2 Gel filtration FPLC of the pooled and concentrated fractions from Q sepharose anion exchange FPLC containing proteolytic/amidolytic activity.
- Anion exchange fractions containing the major peak of proteolytic/amidolytic activity were pooled, equilibrated in TC buffer containing 150 mM NaCl, concentrated and divided into four aliquots and each then independently applied to a gel filtration column (Superose 12 HR 10/30) and eluted using the same buffer at a flow rate of 0 3 ml min ′1 . Fractions (0.5 ml) were assayed for proteolytic and amidolytic activity.
- FIG. 3 SDS-PAGE (boiled/reduced conditions) of the 300 kDa peak from gel filtration (Superose 12 HR 10/30) FPLC. Lane 1, Pharmacia molecular mass standards (M r shown in kDa). Lane 2, 300 kDa peak from gel filtration FPLC. Coomassie blue stained gel.
- FIG. 4 Specific cleavage sites (marked with arrows) of ⁇ S i-casein by the proteolytic/amidolytic peak from gel filtration FPLC corresponding to 300 kDa.
- the protein ⁇ ,i-casein was cleaved on the carboxyl side of arginyl and lysyl residues only (SEQ ID NO:14).
- FIG. 5 Arg-sepharose FPLC of the 300 kDa gel filtration peak exhibiting Arg- and Lys-specific proteolytic activity.
- Gel filtration fractions containing the major peak of proteolytic activity (300 kDa) were pooled and applied to an arginine-sepharose column (5 ml arginine-Sepharose 4B) and washed with TC buffer containing 50 mM NaCl at 0 1 ml min ′′1 until the baseline returned to zero. The column was then further washed with 500 mM NaCl and then re-equilibrated with TC buffer containing 50 mM NaC.
- the column was first eluted with 200 mM lysine in TC buffer containing 50 mM NaCl, followed by 750 mM lysine in the same buffer. The column was then re-equilibrated and eluted with 200 M arginine in the same buffer at a flow rate of 0 1 ml min ′1 . Peaks were collected and assayed for amidolytic and proteolytic activity. Bz-L-Arg-?NA amidolytic activity is shown by the histogram and the arrows indicate the start of each step gradient.
- FIG. 6 SDS-PAGE (boiled/reduced conditions) of 200 mM lysine eluant from the Arg-sepharose FPLC. Lane 1, Pharmacia molecular mass standards (M r shown in kDa) Lane 2, 200 mM lysine eluant from Arg-sepharose FPLC. Silver stained gel.
- FIG. 7 SDS-PAGE (boiled/reduced conditions) of the 750 mM lysine and 200 mM arginine eluants from the arginine-Sepharose FPLC and the purified 45 kDa Arg-specific endopeptidase.
- Lane 1 750 mM lysine eluant.
- Lane 2 200 mM arginine eluant.
- Lane 3 purified 45 kDa Arg-specific endopeptidase.
- Lane 4 Pharmacia molecular mass standards (M r shown in kDa). Coomassie blue stained gel.
- FIG. 8 a Schematic representation of the prtR gene.
- the PrtR nascent polyprotein is composed of a leader sequence, a prosequence followed by the Arg-specific cysteine proteinase PrtR45 (SEQ ID NO:15), and the adhesins PrtR44 (SEQ ID NO:16), PrtR15 (SEQ ID NO:17), PrtR17 (SEQ ID NO:18) and PrtR27 (SEQ ID NO: 19) all preceded by an arginyl or lysyl residue.
- FIG. 8 b Nucleotide sequence of prtR (SEQ ID NO:20 and encoded protein, SEQ ID NO:21).
- FIG. 9 a Schematic representation of the prtK gene.
- the PrtK nascent polyprotein is composed of a leader sequence, a prosequence followed by the Lys-specific cysteine proteinase PrtK48 (SEQ ID NO:22), and the adhesins PrtK39 (SEQ ID NO:19), PrtK 15 (SEQ ID NO:17) and PrtK44 (SEQ ID NO: 18) all preceded by an arginyl or lysyl residue.
- FIG. 9 b Nucleotide sequence of prtK (SEQ ID NO:23 and encoded protein, SEQ ID NO:24).
- FIG. 10 SDS-PAGE of the PrtR-PrtK complex purified by diafiltration. Lane 1 shows molecular mass markers. Lane 2 shows components of the PrtR-PrtK purified by diafiltration.
- FIG. 11 ELISA titration of sera from 5 mice immunized twice with the PrtR-PrtK complex emulsified in Freund's Incomplete Adjuvant.
- Test sera TS 32-36
- pre-immune sera PPS 32-36
- Primary antibody dilutions 1/100, 1/500, 1/2500 and 1/12500 were used.
- Bound antibody was determined using horseradish peroxidase-conjugated goat anti-mouse antibody and 3,3′,5,5′tetramethylbenezidine.
- the reaction product was quantitated spectrophotometrically using a 450 nm interference filter in a plate reader and recorded as optical density (O D ) readings.
- the intra-oral bacterium Porphyromonas gingivalis possesses on its cell surface major trypsin-like proteinases as a 294-323 kDa heterodimeric protein complex of Arg-specific and Lys-specific thiol endopeptidases with hemagglutinins (adhesins) herein designated the PrtR-PrtK complex.
- the PrtR-PrtK complex can be purified from P. gingivalis cells by ultrasonication or chloroform extraction followed by diafiltration or anion exchange and Lys-sepharose or Arg-sepharose chromatography. The purified PrtR-PrtK complex is then used to generate antibodies using standard techniques.
- the animals used for antibody generation can be rabbits, goats, chickens, sheep, horses, cows etc.
- a high antibody titre against the PrtR-PrtK complex is detected by immunoassay the animals are bled or eggs or milk are collected and the serum prepared and/or antibody purified using standard techniques or monoclonal antibodies produced by fusing spleen cells with myeloma cells using standard techniques.
- the antibody immunoglobulin fraction
- the antiserum or the milk is saturated with ammonium sulphate to produce a precipitate, followed by dialyzing the precipitate against physiological saline to obtain the purified immunoglobulin fraction with the specific anti-(PrtR-PrtK).
- the preferred antibody is obtained from the equine antiserum and the bovine antiserum and milk.
- the antibody contained in the antiserum and milk obtained by immunising the animal with the inactivated PrtR-PrtK may be blended into the oral composition.
- the antiserum and milk as well as the antibody separated and purified from the antiserum and milk may be used Each of these materials may be used alone or in combination of two or more.
- Antibodies against the PrtR-PrtK can be used in oral compositions such as toothpaste and mouthwash to neutralise the PrtR-PrtK and thus prevent disease.
- the anti-(PrtR-PrtK) antibodies can also be used for the early detection of P. gingivalis in subgingival plaque samples by a chairside Enzyme Linked Immunosorbent Assay (ELISA).
- the amount of the above antibodies administered is 00001-50 g kg/day and that the content of the above antibodies is 00002-10% by weight preferably 0002-5% by weight of the composition.
- the oral composition of this invention contains the above-mentioned serum or milk antibody may be prepared and used in various forms applicable to the mouth such as dentifrice including toothpastes, toothpowders and liquid dentifrices, mouthwashes, troches, periodontal pocket irrigating devices, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products and other foodstuffs.
- the oral composition according to this invention may further include additional well known ingredients depending on the type and form of a particular oral composition.
- the oral composition may be substantially liquid in character, such as a mouthwash or rinse.
- the vehicle is typically a water-alcohol mixture desirably including a humectant as described below.
- the weight ratio of water to alcohol is in the range of from about 1 1 to about 20 1.
- the total amount of water-alcohol mixture in this type of preparation is typically in the range of from about 70 to about 99 9% by weight of the preparation.
- the alcohol is typically ethanol or isopropanol. Ethanol is preferred.
- the pH of such liquid and other preparations of the invention is generally in the range of from about 4 5 to about 9 and typically from about 5 5 to 8.
- the pH is preferably in the range of from about 6 to about 8 0, preferably 7 4.
- the pH can be controlled with acid (e g citric acid or benzoic acid) or base (e g sodium hydroxide) or buffered (as with sodium citrate, benzoate, carbonate, or bicarbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, etc).
- the oral composition may be substantially solid or pasty m character, such as toothpowder, a dental tablet or a dentifrice, that is a toothpaste (dental cream) or gel dentifrice.
- the vehicle of such solid or pasty oral preparations generally contains dentally acceptable polishing material.
- polishing materials are water-insoluble sodium metaphosphate, potassium metaphosphate, tricalcium phosphate, dihydrated calcium phosphate, anhydrous dicalcium phosphate, calcium pyrophosphate, magnesium orthophosphate, trimagnesium phosphate, calcium carbonate, hydrated alumina, calcined alumina, aluminium silicate, zirconium silicate, silica, bentonite, and mixtures thereof.
- polishing material include the particulate thermosetting resins such as melamine-, phenolic, and urea-formaldehydes, and cross-linked polyepoxides and polyesters.
- Preferred polishing materials include crystalline silica having particle sized of up to about 5 microns, a mean particle size of up to about 1.1 microns, and a surface area of up to about 50,000 cm 2 /gm., silica gel or colloidal silica, and complex amorphous alkali metal aluminosilicate.
- a polishing agent of colloidal silica such as those sold under the trademark SYLOID as Syloid 72 and Syloid 74 or under the trademark SANTOCEL as Santocel 100
- alkali metal alumino-silicate complexes are particularly useful since they have refractive indices close to the refractive indices of gelling agent-liquid (including water and/or humectant) systems commonly used in dentifrices.
- insoluble sodium metaphosphate may be formed in any suitable manner as illustrated by Thorpe's Dictionary of Applied Chemistry, Volume 9, 4th Edition, pp. 510-51 1.
- the forms of insoluble sodium metaphosphate known as Madrell's salt and Kurrol's salt are further examples of suitable materials.
- These metaphosphate salts exhibit only a minute solubility in water, and therefore are commonly referred to as insoluble metaphosphates (IMP).
- IMP insoluble metaphosphates
- impurities usually a few percent such as up to 4% by weight.
- the amount of soluble phosphate material which is believed to include a soluble sodium trimetaphosphate in the case of insoluble metaphosphate, may be reduced or eliminated by washing with water if desired.
- the insoluble alkali metal metaphosphate is typically employed in powder form of a particle size such that no more than 1% of the material is larger than 37 microns.
- the polishing material is generally present in the solid or pasty compositions in weight concentrations of about 10% to about 99%. Preferably, it is present in amounts from about 10% to about 75% in toothpaste, and from about 70% to about 99% in toothpowder. In toothpastes, when the polishing material is silicious in nature, it is generally present in amount of about 10-30% by weight. Other polishing materials are typically present in amount of about 30-75% by weight.
- the liquid vehicle may comprise water and humectant typically in an amount ranging from about 10% to about 80% by weight of the preparation.
- humectant typically in an amount ranging from about 10% to about 80% by weight of the preparation.
- Glycerine, propylene glycol, sorbitol and polypropylene glycol exemplify suitable humectants/carriers.
- liquid mixtures of water, glycerine and sorbitol are particularly advantageous. In clear gels where the refractive index is an important consideration, about 2.5-30% w/w of water, 0 to about 70% w/w of glycerine and about 20-80% w/w of sorbitol are preferably employed.
- Toothpaste, creams and gels typically contain a natural or synthetic thickener or gelling agent in proportions of about 0.1 to about 10, preferably about 0.5 to about 5% w/w.
- a suitable thickener is synthetic hectorite, a synthetic colloidal magnesium alkali metal silicate complex clay available for example as Laponite (e.g. CP, SP 2002, D) marketed by Laporte Industries Limited.
- Laponite D is, approximately by weight 58.00% SiO 2 , 25.40% MgO, 3.05% Na 2 O, 0.98% Li 2 O, and some water and trace metals. Its true specific gravity is 2.53 and it has an apparent bulk density of 1.0 g/ml at 8% moisture.
- thickeners include Irish moss, iota carrageenan, gum tragacanth, starch, polyvinylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutyl methyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose (e.g. available as Natrosol), sodium carboxymethyl cellulose, and colloidal silica such as finely ground Syloid (e.g. 244).
- Irish moss iota carrageenan
- gum tragacanth starch
- polyvinylpyrrolidone hydroxyethylpropylcellulose
- hydroxybutyl methyl cellulose hydroxypropyl methyl cellulose
- sodium carboxymethyl cellulose hydroxyethyl cellulose
- colloidal silica such as finely ground Syloid (e.g. 244).
- Solubilizing agents may also be included such as humectant polyols such propylene glycol, dipropylene glycol and hexylene glycol, cellosolves such as methyl cellosolve and ethyl cellosolve, vegetable oils and waxes containing at least about 12 carbons in a straight chain such as olive oil, castor oil and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate.
- humectant polyols such propylene glycol, dipropylene glycol and hexylene glycol
- cellosolves such as methyl cellosolve and ethyl cellosolve
- vegetable oils and waxes containing at least about 12 carbons in a straight chain such as olive oil, castor oil and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate.
- ajar of mouthrinse will have a label describing it, in substance, as a mouthrinse or mouthwash and having directions for its use, and a toothpaste, cream or gel will usually be in a collapsible tube, typically aluminium, lined lead or plastic, or other squeeze, pump or pressurised dispenser for metering out the contents, having a label describing it, in substance, as a toothpaste, gel or dental cream.
- Organic surface-active agents are used in the compositions of the present invention to achieve increased prophylactic action, assist in achieving thorough and complete dispersion of the active agent throughout the oral cavity, and render the instant compositions more cosmetically acceptable.
- the organic surface-active material is preferably anionic, nonionic or ampholytic in nature which does not denature the antibody of the invention, and it is preferred to employ as the surface-active agent a detersive material which imparts to the composition detersive and foaming properties while not denaturing the antibody
- anionic surfactants are water-soluble salts of higher fatty acid monoglyceride monosulfates, such as the sodium salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids, higher alkyl sulfates such as sodium lauryl sulfate, alkyl aryl sulfonates such as sodium dodecyl benzene sulfonate, higher alkylsulfo-acetates, higher fatty acid esters of 1,2-
- Examples of the last mentioned amides are N-lauroyl sarcosine, and the sodium, potassium, and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine which should be substantially free from soap or similar higher fatty acid material.
- the use of these sarconite compounds in the oral compositions of the present invention is particularly advantageous since these materials exhibit a prolonged marked effect in the inhibition of acid formation in the oral cavity due to carbohydrates breakdown in addition to exerting some reduction in the solubility of tooth enamel in acid solutions.
- Examples of water-soluble nonionic surfactants suitable for use with antibodies are condensation products of ethylene oxide with various reactive hydrogen-containing compounds reactive therewith having long hydrophobic chains (e.g.
- condensation products contain hydrophilic polyoxyethylene moieties, such as condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols (e.g sorbitan monostearate) and polypropyleneoxide (e.g. Pluronic materials).
- Surface active agent is typically present in amount of about 0. 1-5% by weight. It is noteworthy, that the surface active agent may assist in the dissolving of the antibody of the invention and thereby diminish the amount of solubilizing humectant needed.
- Various other materials may be incorporated in the oral preparations of this invention such as whitening agents, preservatives, silicones, chlorophyll compounds and/or ammoniated material such as urea, diammonium phosphate, and mixtures thereof.
- whitening agents such as whitening agents, preservatives, silicones, chlorophyll compounds and/or ammoniated material such as urea, diammonium phosphate, and mixtures thereof.
- flavouring or sweetening material may also be employed.
- suitable flavouring constituents are flavouring oils, e.g. oil of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, and orange, and methyl salicylate.
- suitable sweetening agents include sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartine, AMP (aspartyl phenyl alanine, methyl ester), saccharine, and the like.
- flavour and sweetening agents may each or together comprise from about 0 1% to 5% more of the preparation.
- an oral composition according to this invention such as mouthwash or dentifrice containing the composition of the present invention is preferably applied regularly to the gums and teeth, such as every day or every second or third day or preferably from 1 to 3 times daily, at a pH of about 4 5 to about 9, generally about 5 5 to about 8, preferably about 6 to 8, for at least 2 weeks up to 8 weeks or more up to a lifetime.
- compositions of this invention can be incorporated in lozenges, or in chewing gum or other products, e.g by stirring into a warm gum base or coating the outer surface of a gum base, illustrative of which may be mentioned jelutong, rubber latex, vinylite resins, etc, desirably with conventional plasticisers or softeners, sugar or other sweeteners or such as glucose, sorbitol and the like.
- composition of this invention also includes targeted delivery vehicles such as periodontal pocket irrigation devices, collagen, elastin, or synthetic sponges, membranes or fibres placed in the periodontal pocket or used as a barrier membrane or applied directly to the tooth root.
- targeted delivery vehicles such as periodontal pocket irrigation devices, collagen, elastin, or synthetic sponges, membranes or fibres placed in the periodontal pocket or used as a barrier membrane or applied directly to the tooth root.
- Another important form of the invention is a composition for use in eliciting an immune response directed against Porphyromonas gingivalis based on the PrtR-PrtK complex and suitable adjuvant delivered by nasal spray, orally or by injection to produce a specific immune response against the PrtR-PrtK complex thereby reducing colonisation of P. gingivalis and neutralising the PrtR-PrtK thereby preventing disease. Due to the potent enzymatic activity of the complex typically the complex will be inactivated.
- a vaccine can also be based upon a recombinant component of the PrtR-PrtK incorporated into an appropriate vector and expressed in a suitable transformed host (eg E.
- the PrtR-PrtK complex is a safe and effective antigens for the preparation of a composition for use in the prevention of P. gingivalis -associated periodontal disease.
- the PrtR-PrtK complex can be produced using recombinant DNA methods as illustrated herein, or can be synthesized chemically from the amino acid sequence disclosed in the present invention. Additionally, according to the present invention, the PrtR-PrtK complex may be used to generate antisera useful for passive immunization against periodontal disease and infections caused by P. gingivalis.
- adjuvants are used in conjunction with vaccine formulations.
- the adjuvants aid by modulating the immune response and in attaining a more durable and higher level of immunity using smaller amounts of vaccine antigen or fewer doses than if the vaccine antigen were administered alone.
- adjuvants include incomplete Freund's adjuvant (IF A), Adjuvant 65 (containing peanut oil, mannide monooleate and aluminium monostrearate), oil emulsions, Ribi adjuvant, the pluronic polyols, polyamines, Avridine, Quil A, saponin, MPL, QS-21, and mineral gels such as aluminium salts.
- the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, buffers or diluents as appropriate.
- One or more doses of the vaccine containing adjuvant may be administered prophylactically to prevent periodontitis or therapeutically to treat already present periodontitis.
- the preparation is combined with a mucosal adjuvant and administered via the oral route.
- mucosal adjuvants are cholera toxin and heat labile E. coli toxin, the non-toxic B subunits of these toxins, genetic mutants of these toxins which have a reduced toxicity.
- Other methods which may be utilised to deliver the PrtR-PrtK complex orally include incorporation of the protease into particles of biodegradable polymers (such as acrylates or polyesters) by microencapsulation to aid uptake of the microspheres from the gastrointestinal tract and to protect degradation of the proteins.
- Liposomes, ISCOMs, hydrogels are examples of other potential methods which may be further enhanced by the incorporation of targeting molecules such as LTB, CTB or lectins for delivery of the PrtR-PrtK complex to the mucosal immune system.
- targeting molecules such as LTB, CTB or lectins for delivery of the PrtR-PrtK complex to the mucosal immune system.
- the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, coatings, dispersion media, antibacterial and antifungal agents, buffers or diluents as appropriate.
- Another mode of this embodiment provides for either a live recombinant viral vaccine, recombinant bacterial vaccine, recombinant attenuated bacterial vaccine, or an inactivated recombinant viral vaccine which is used to protect against infections caused by P. gingivalis .
- Vaccinia virus is the best known example, in the art, of an infectious virus that is engineered to express vaccine antigens derived from other organisms.
- the recombinant live vaccinia virus which is attenuated or otherwise treated so that it does not cause disease by itself, is used to immunize the host. Subsequent replication of the recombinant virus within the host provides a continual stimulation of the immune system with the vaccine antigens such as PrtR-PrtK complex, thereby providing long lasting immunity.
- live vaccine vectors include adenovirus, cytomegalovirus, and preferably the poxviruses such as vaccinia (Paoletti and Panicali, U.S. Pat. No 4,603,112) and attenuated Salmonella strains (Stocker et al, U.S. Pat. Nos. 5,210,035, 4,837,151, and 4,735,801, and Curtiss e/fl/, 1988, Vaccine 6.155-160). Live vaccines are particularly advantageous because they continually stimulate the immune system which can confer substantially long-lasting immunity. When the immune response is protective against subsequent P. gingivalis infection, the live vaccine itself may be used in a preventive vaccine against P. gingivalis .
- poxviruses such as vaccinia (Paoletti and Panicali, U.S. Pat. No 4,603,112) and attenuated Salmonella strains (Stocker et al, U.S. Pat. Nos. 5,210,035, 4,837,
- the live vaccine can be based on a bacterium that is a commensal inhabitant of the oral cavity.
- This bacterium can be transformed with a vector carrying a recombinant inactivated PrtR-PrtK and then used to colonise the oral cavity, in particular the oral mucosa. Once colonised the oral mucosa, the expression of the recombinant protein will stimulate the mucosal associated lymphoid tissue to produce neutralising antibodies.
- the genes encoding the PrtR-PrtK may be inserted into the vaccinia virus genomic DNA at a site which allows for expression of epitopes but does not negatively affect the growth or replication of the vaccinia virus vector.
- the resultant recombinant virus can be used as the immunogen in a vaccine formulation.
- the same methods can be used to construct an inactivated recombinant viral vaccine formulation except that the recombinant virus is inactivated, such as by chemical means known in the art, prior to use as an immunogen and without substantially affecting the immunogenicity of the expressed immunogen.
- nucleic acid DNA or RNA
- sequences encoding the PrtR-PrtK protein complex operatively linked to one or more regulatory elements can be introduced directly to vaccinate the individual (“direct gene transfer”) against pathogenic strains of P. gingivalis
- Direct gene transfer into a vaccinated individual, resulting in expression of the genetic material by the vaccinated individual's cells such as vascular endothelial cells as well as the tissue of the major organs has been demonstrated by techniques in the art such as by injecting intravenously an expression plasmid cationic liposome complex (Zhu et al, 1993, Science 261 209-211 ).
- recombinant plasmid DNA containing viral genes has been used to inoculate (whether parentally, mucosally, or via gene-gun immunization) vaccines to induce a protective immune response (Fynan et al 1993, Proc Natl Acad Sci USA 90 11478-11482).
- cells removed from an individual can be transfected or electroporated by standard procedures known in the art, resulting in the introduction of the recombinant vector DNA into the target cell.
- Cells containing the recombinant vector DNA may then be selected for using methods known in the art such as via a selection marker expressed in the vector, and the selected cells may then be re-introduced into the individual to express the PrtR-PrtK complex.
- immunization may be passive, i e immunization comprising administration of purified immunoglobulin containing antibody against PrtR-PrtK.
- the present invention further provides the nucleotide sequence of the genes encoding the PrtR-PrtK complex, as well as the amino acid sequence deduced from the isolated genes.
- the genes encoding the PrtR-PrtK complex are incorporated into an expression vector, and the recombinant vector is introduced into an appropriate host cell thereby directing the expression of these sequences in that particular host cell.
- the expression system comprising the recombinant vector introduced into the host cell, can be used (a) to produce PrtR-PrtK complex which can be purified for use as an immunogen in vaccine formulations, (b) to produce PrtR-PrtK complex to be used as an antigen for diagnostic immunoassays or for generating P.
- the recombinant expression vector is a live virus such as vaccinia virus
- the vector itself may be used as a live or inactivated vaccine preparation to be introduced into the host's cells for expression of PrtR-PrtK complex
- the vector itself may be used as a live or inactivated vaccine preparation to be introduced into the host's cells for expression of PrtR-PrtK complex
- the vector for introduction into live attenuated bacterial cells or genetically engineered commensal intra-oral bacteria which are used to express PrtR-PrtK complex to vaccinate individuals
- the recombinant bacterial vaccine can be based on a commensal inhabitant of the human oral cavity or animal if the vaccine is to prevent periodontal disease in animals.
- the recombinant bacterial vaccine expressing inactivated PrtR-PrtK can be used to colonise the oral cavity, supragingival or subgingival plaque.
- the intra-oral bacterium can be isolated from the patient with periodontitis and genetically engineered to express inactivated PrtR-PrtK complex.
- the production of the inactivated PrtR-PrtK within the oral cavity will not be toxic to the oral mucosal tissues.
- the inactivated PrtR-PrtK will stimulate the mucosal-associated lymphoid tissues (MALT) to produce specific antibody to neutralise the PrtR-PrtK of P. gingivalis.
- MALT mucosal-associated lymphoid tissues
- PrtR-PrtK a variety of host systems may be utilized to express the PrtR-PrtK, which include, but are not limited to bacteria transformed with a bacteriophage vector, plasmid vector, or cosmid DNA; yeast containing yeast vectors; fungi containing fungal vectors, insect cell lines infected with virus (e.g baculovirus); and mammalian cell lines transfected with plasmid or viral expression vectors, or infected with recombinant virus (e.g vaccinia virus, adenovirus, adeno-associated virus, retrovirus, etc).
- promoters and enhancers can be incorporated into the vector or the DNA sequence encoding PrtR-PrtK to increase the expression of the PrtR-PrtK amino acid sequences, provided that the increased expression of the amino acid sequences is compatible with (for example, non-toxic to) the particular host cell system used.
- the DNA can be fused to DNA encoding other antigens, such as other bacterial outer membrane proteins, or other bacterial, fungal, parasitic, or viral antigens to create a genetically fused (sharing a common peptide backbone) multivalent antigen for use as an improved vaccine composition.
- promoter will depend on the expression system used. Promoters vary in strength, i.e. ability to facilitate transcription. Generally, for the purpose of expressing a cloned gene, it is desirable to use a strong promoter in order to obtain a high level of transcription of the gene and expression into gene product. For example, bacterial, phage, or plasmid promoters known in the art from which a high level of transcription have been observed in a host cell system comprising E.
- coli include the lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the P R and P L promoters, lacUV5, ompF, bla, 1 pp, and the like, may be used to provide transcription of the inserted DNA sequence encoding PrtR-PrtK.
- PrtR-PrtK protein may be lethal or detrimental to the host cells
- the host cell strain/line and expression vectors may be chosen such that the action of the promoter is inhibited until specifically induced.
- the addition of specific inducers is necessary for efficient transcription of the inserted DNA (e g, the lac operon is induced by the addition of lactose or isopropylthio-beta-D-galactoside).
- the trp operon are under different control mechanisms
- the trp operon is induced when tryptophan is absent in the growth media.
- the P promoter can be induced by an increase in temperature of host cells containing a temperature sensitive lambda repressor.
- telomere-directed transcription may be inhibited in uninduced cells.
- expression of recombinant PrtR-PrtK protein may be controlled by,culturing transformed or transfected cells under conditions such that the promoter controlling the expression from the inserted DNA encoding PrtR-PrtK amino acid sequences is not induced, and when the cells reach a suitable density in the growth medium, the promoter can be induced for expression from the inserted DNA.
- Enhancer sequences are DNA elements that appear to increase transcriptional efficiency in a manner relatively independent of their position and orientation with respect to a nearby gene. Thus, depending on the host cell expression vector system used, an enhancer may be placed either upstream or downstream from the inserted DNA sequences encoding PrtR-PrtK amino acid sequences to increase transcriptional efficiency. These or other regulatory sites, such as transcription or translation initiation signals, can be used to regulate the expression of the gene encoding PrtR-PrtK. Such regulatory elements may be inserted into DNA sequences encoding PrtR-PrtK amino acid sequences or nearby vector DNA sequences using recombinant DNA methods described herein for insertion of DNA sequences.
- P. gingivalis nucleotide sequences containing regions encoding for PrtR-PrtK can be ligated into an expression vector at a specific site in relation to the vector's promoter, control, and regulatory elements so that when the recombinant vector is introduced into the host cell the P. gingivalis -specific DNA sequences can be expressed in the host cell.
- the PrtR-PrtK specific DNA sequences containing their own regulatory elements can be ligated into an expression vector in a relation or orientation to the vector promoter and control elements which will allow for co-expression of the PrtR and PrtK.
- the recombinant vector is then introduced into the appropriate host cells, and the host cells are selected, and screened for those cells containing the recombinant vector. Selection and screening may be accomplished by methods known in the art including detecting the expression of a marker gene (e.g, drug resistance marker) present in the plasmid, immunoscreening for production of PrtR-PrtK specific epitopes using antisera generated to PrtR-PrtK specific epitopes, and probing the DNA of the host's cells for PrtR-PrtK specific nucleotide sequence using one or more oligonucleotides and methods described herein.
- a marker gene e.g, drug resistance marker
- Genetic engineering techniques may also be used to characterize, modify and/or adapt the encoded PrtR-PrtK protein. For example, site-directed mutagenesis to inactivate the protease domains of the PrtR-PrtK and to modify the protein in regions outside the protective domains, may be desirable to increase the safety and solubility.
- the host organism for the vector containing the PrtR-PrtK genes and constructs can be a commensal inhabitant of the oral cavity; for example an inhabitant of subgingival plaque, supragingival plaque or a bacterium associated with the oral mucosa
- commensal intra-oral bacteria would be Streptococcus species and Actinomyces species, eg Streptococcus salivarius, Streptococcus sanguis, Actinomyces naeslundii. These organisms can be isolated from the periodontitis patient and then genetically engineered to express the inactivated PrtR-PrtK.
- the DNA encoding the PrtR-PrtK could be linked with DNA encoding leader sequences of extracellular proteins of these commensal intra-oral bacteria.
- the DNA encoding the PrtR-PrtK could also be linked with, or inserted into, the DNA encoding extracellular proteins to produce secreted fusion proteins.
- extracellular proteins that could be used to produce fusion proteins with the inactivated PrtR-PrtK could be the glucosyltranferases (GTF) or fructosyltransferases (FTF).
- the recombinant organism would be then re-introduced into the patients oral cavity and once colonised the oral mucosa or teeth would express the inactivated PrtR-PrtK to stimulate the mucosal associated lymphoid tissue to produce neutralising antibodies.
- the nucleic acid sequences of the present invention can be used in molecular diagnostic assays for detecting P. gingivalis genetic material.
- PrtR-PrtK sequence-specific oligonucleotides can be synthesized for use as primers and/or probes in amplifying, and detecting amplified, nucleic acids from P. gingivalis .
- Recent advances in molecular biology have provided several means for enzymaticaUy amplifying nucleic acid sequences.
- LCRTM ligase chain reaction, BioTechnica International
- QB replicase Gene-Trak Systems
- RNA ribonucleic acid sequence template attached to a probe complementary to the DNA to be copied which is used to make a DNA template for exponential production of complementary RNA
- NASBATM nucleic acid sequence-based amplification, Cangene Corporation
- Nucleic acid probes that are capable of hybridization with specific gene sequences have been used successfully to detect specific pathogens in biological specimens at levels of sensitivity approaching 10 3 -10 4 organisms per specimen (1990, Gene Probes for Bacteria, eds Macario and deMacario, Academic Press). Coupled with a method that allows for amplification of specific target DNA sequences, species-specific nucleic acid probes can greatly increase the level of sensitivity in detecting organisms in a clinical specimen. Use of these probes may allow direct detection without relying on prior culture and/or conventional biochemical identification techniques. This embodiment of the present invention is directed to primers which amplify species-specific sequences of the genes encoding PrtR-PrtK of P.
- DNA may be extracted from clinical specimens which may contain P. gingivalis using methods known in the art. For example, cells contained in the specimen may be washed in TE buffer and pelleted by centrifugation. The cells then may be resuspended in 100 ul of amplification reaction buffer containing detergents and proteinase K Using the polymerase chain reaction, the resultant sample may be composed of the cells in 10 mM Tris pH 8 3, 50 mM KCl, 1 5mM MgCl 2 , 0 01% gelatin, 045% NP40TM, 0 045% Tween 20TM, and 60 ug/ml proteinase K. The sample is incubated in a 55° C. water bath for l hour. Following the incubation, the sample is incubated at 95° C. for 10 minutes to heat-inactivate the proteinase K. The sample may then be amplified in accordance with standard PCR protocols.
- gingivalis was grown to late logarithmic phase and the cells harvested by centrifugation (5,000 ⁇ g, 20 min, 4° C.) and then resuspended in 160 ml TC buffer (20 mM Tris-HCl pH 7 4 and 5 mM CaCl 2 ) containing 50 mM NaCl and subjected to mild sonication using a Branson Sonifier 250 with an output control of 3 and a 50% duty cycle for 15 min at 4° C. The sonicate was centrifuged (100,000 ⁇ 30 min, 4° C.) and the supernatant filtered (0.22 ⁇ m) prior to anion-exchange FPLC.
- the sonicate was applied to an anion-exchange column (Hiload XK 16/10 Q Sepharose, Pharmacia-LKB) cooled to 4° C., in multiple injections using a 50 ml superloop (Pharmacia-LKB).
- the sample was eluted using a linear gradient from 0-100% buffer B over 90 min at a flow rate of 2 0 ml min ′′1 .
- the eluant was monitored at 280 nm and collected in 6 ml fractions using a Frac 100 fraction collector (Pharmacia-LKB).
- Buffer A was TC buffer containing 50 mM NaCl and buffer B was TC buffer containing 500 mM NaCl.
- the sample was then divided into four aliquots and each was independently applied to a gel filtration column (Superose 12, HR 10/30, Pharmacia-LKB) using TC buffer containing 150 mM NaCl at a flow rate of 0 3 ml min ′′1 .
- the eluant was monitored at 280 nm and peaks collected using a Frac 100 fraction collector
- the M ⁇ values of eluant peaks were determined using molecular mass gel filtration standards (Pharmacia-LKB)
- the peak containing the majority of the proteolytic/amidolytic activity was concentrated using a centricon 10 micro-concentrator and then applied at a flow rate of 0 1 ml min ′′ to an Arg-sepharose column (5 ml arginine-Sepharose 4B beads, HR 5/5 column, Pharmacia-LKB) and the unbound material collected.
- the column was washed with 500 mM NaCl and re-equilibrated with TC buffer containing 50 mM NaCl
- the column was first eluted with 200 mM lysine-HCl pH 7.4 in TC buffer containing 50 mM NaCl at a flow rate of 0.1 ml min ′′1 . This was followed by 750 mM lysine-HCl pH 7.4 in the same buffer.
- the column was then re-equilibrated with TC buffer containing 50 mM NaCl and then eluted with 200 mM arginine-HCl pH 7.4 in TC buffer containing 50 mM NaCl at a flow rate of 0.1 ml min ′′1 .
- the unbound material collected was then re-applied to the Arg-sepharose column and the elution steps repeated. This sequence was repeated until all proteolytic activity had bound to the column.
- the eluant was monitored at 280 nm and peaks collected using a Frac 100 fraction collector.
- Buffer A was TC buffer containing 50 mM NaCl and 0.1% octyl- ⁇ -D-glucopyranoside and buffer B was TC buffer containing 500 mM NaCl and 0.1% octyl- ⁇ -D-glucopyranoside.
- the eluant was monitored at 280 nm and eluant peaks collected using a Frac 100 fraction collector.
- Azocasein, and z-L-lys-Na were used to routinely assay FPLC fractions for proteolytic and amidolytic activity.
- a sample of each fraction (20-200:1) was incubated at 37° C. with azocasein (5 mg/ml final concentration) in TC buffer pH 8.0 containing 150 mM NaCl and 10 mM cysteine.
- azocasein the reaction was stopped by the addition of 30% trichloroacetic acid at 4° C. Samples were centrifuged and the wo of the supernatant measured using a spectrophotometer (Perkin Elmer, model 552).
- Buffer B was 80% acetonitrile (v/v) in 0 1% (v/v) TFA in Milli Q water. The eluant was monitored at 214 nm using a 1000S diode array detector (Applied Biosystems). Peaks were collected manually and peptides identified using a combination of amino acid composition and sequence analyses as described previously.
- SDS-PAGE was performed using a Mini protean II electrophoresis system (Biorad) with 12% (w/v), 1 mm separating gels, overlaid with 5% stacking gels (Laemmli, 1970) [Nature 277 680-685]. Two volumes of each sample were mixed with one volume of buffer [0 5 M Tris-HCl, pH 6 8, 5% v/v 2-mercaptoethanol, 10 0% w/v SDS, 0 05% w/v bromophenol blue (75% v/v) and glycerol (25% v/v)] and heated to 100° C.
- buffer 0 5 M Tris-HCl, pH 6 8, 5% v/v 2-mercaptoethanol, 10 0% w/v SDS, 0 05% w/v bromophenol blue (75% v/v) and glycerol (25% v/v)
- SDS-PAGE was performed at room temperature using a current of 30-50 mA and a potential difference of ⁇ 200 V.
- gels were fixed in methanol/water/acetic acid (45/45/10, v/v/v), washed in Milli Q water, reduced with 5 ⁇ g/ml dithiothreitol and then washed in Milli Q water, all for 30 min periods. Gels were then stained for 20 min with 0 1% w/v AgNO 3 and developed with 3% w/v sodium carbonate containing 0 1% v/v formaldehyde and development stopped with glacial acetic acid.
- the ultrasonication procedure was effective at releasing the cell-associated Arg- and Lys-specific proteolytic activity of P. gingivalis W50 and 15 min was required for maximal release of activity.
- the sonicate of P. gingivalis W50 cells contained 0 30 mg ml ′′1 protein and 2 6 and 2 3 ⁇ mol min ⁇ 1 mg protein ′′1 activity with 1 0 mM Bz-L-Arg-pNA and z-L-Lys-pNA as substrate respectively at 37° C.
- the crude sonicate was subjected to Q-sepharose anion exchange FPLC and a representative chromatogram is presented in FIG.
- Proteolytic/amidolytic activity eluted as one major peak between 246-320 mM NaCl ( FIG. 1 ) which was collected, concentrated using a centricon-10 (Amicon) and then applied to the Superose 12 gel filtration column ( FIG. 2 )
- Molecular mass gel filtration standards were used to determine the of the peaks obtained and the major peak, which also exhibited the major proteolytic/amidolytic activity, corresponded to 300 kDa ( FIG. 2 )
- Proteolytic/amidolytic activity was also associated with the high molecular mass material (0 6 ⁇ 2 0 ⁇ 10 6 Da) eluted from the gel filtration column.
- the 300 kDa gel filtration peak contained seven bands at 48, 45, 44, 39, 27, 17 and 15 kDa on SDS-PAGE analysis ( FIG. 3 ).
- the seven bands were transblotted and subjected to N-terminal sequence analysis (Table 1).
- This analysis revealed that the 44 kDa band contained two proteins and the N-terminal sequences of these two 44 kDa proteins were assigned after further purification
- the N-terminal sequence of one of the 44 kDa proteins was identical to that of the 1 7 kDa protein and the 39 kDa and 27 kDa proteins also had identical N-termini (Table 1).
- N-terminal sequences of proteins in the 300 kDa complex separated by SDS-PAGE Band N-terminal sequence (kDa) 48* DVYTDHGDLYNTPVRML (SEQ ID NO:1) 45 ⁇ YTPVEEKQNGRMIVIVAKKYEGD (SEQ ID NO:2) 44 ⁇ SGQAEIVLEAHDVWNDGSGYQILLDADHDQYGQVIPSDTHFL (SEQ ID NO:3) 44* PQSVWIERTVDLPAGTKYVAFR (SEQ ID NO:4) 39* ANEAKVVLAADNVWGDNTGYQFLLDA (SEQ ID NO:5) 27 ⁇ ANEAKVVLAADNVWGDNTGYQFLLDA (SEQ ID NO:6) 17 ⁇ PQSVWIERTVDLPAGTKYVAFR (SEQ ID NO:7) 15* ⁇ ADFTETFESSTHGEAPAEWTTIDA (SEQ ID NO:8) *Proteins eluted from Arg-sepharose by 200 mM
- the 300 kDa gel filtration protein complex was incubated with ⁇ ,i-casein.
- the ⁇ ,i-casein peptides released by the action of the proteolytic activity of the 300 kDa complex were purified by RP-HPLC and identified by amino acid composition and sequence analyses.
- the sites of ⁇ ,i-casein cleavage by the material of the 300 kDa complex were the carboxyl side of arginyl and lysyl residues only ( FIG. 4 ). All arginyl and lysyl residues of ⁇ ,i-casein were cleaved except the N-terminal Arg and the Lys residues flanking the Ser(P) cluster sequence, presumably due to the high negative charge density ( FIG. 4 ).
- the 300 kDa complex was then applied to an Arg-sepharose column and washed with TC buffer containing 500 mM NaCl ( FIG. 5 ).
- the Arg-sepharose was eluted first with 200 mM lysine in TC buffer ( FIG. 5 ) which eluted a small amount of the 48 kDa, 44 kDa, 39 kDa and 15 kDa proteins of the 300 kDa complex as shown by SDS-PAGE ( FIG. 6 and Table 1). N-terminal sequence analysis of these transblotted proteins revealed that only one of the 44 kDa proteins of the 300 kDa complex was eluted with 200 mM lysine (Table 1).
- the Arg-sepharose column was eluted with 750 mM lysine ( FIG. 5 ) which removed the majority of the protein bound as the undissociated 300 kDa complex containing all seven bands (eight proteins) as shown by SDS-PAGE analysis ( FIG. 7 )
- the 750 mM lysine eluant exhibited both Arg- and Lys-specific proteolytic/amidolytic activity characteristic of the 300 kDa complex.
- the Arg-sepharose column was then eluted with 200 mM arginine in TC buffer ( FIG.
- the 200 mM arginine eluant contained small amounts of the 45, 44, 27, 17 and 15 kDa proteins as shown by SDS-PAGE ( FIG. 7 ). This fraction exhibited only Arg-specific proteolytic/amidolytic activity. N-terminal sequence analysis of these transblotted proteins eluted with 200 mM arginine revealed that only one of the 44 kDa proteins of the 300 kDa complex was eluted with 200 mM arginine and this 44 kDa protein was different to the 44 kDa protein eluted with 200 mM lysine (Table 1).
- the proteins eluted from the Arg-sepharose column with 200 mM lysine and 200 mM arginine were washed, concentrated and equilibrated with TC buffer containing 50 mM NaCl and 1 0% octyl- ⁇ -D-glucopyranoside and applied independently to a Mono Q anion exchange column. Elution from the Mono Q column with a NaCi gradient associated the Arg-specific proteolytic activity with the 45 kDa protein with a 25 fold purification over the original crude sonicate (Table 2, FIG. 7 ).
- the specificity of the 45 kDa proteinase for arginyl residues was confirmed by the enzyme cleaving Bz-L-Arg-pNA but not z-L-Lys-pNA
- the Arg-specific 45 kDa enzyme was activated by thiols (particularly cysteine), not inhibited by PMSF or AEBSF but inhibited by sulphydryl-directed reagents, leupeptin and EDTA (Table 3).
- the inhibition by EDTA could be reversed by the addition of Ca 2* (Table 3).
- the pH optimum of the enzyme was 7 5-8 0 and activity dropped off dramatically as the pH was lowered below 7 0
- the Lys-specific activity was characterized using the substrate Z-L-Lys-pNA and was associated with the 48 kDa protein purified from the 200 mM lysine eluant by Mono Q FPLC.
- the Lys-specific enzyme was also activated by thiols and inhibited by sulphydryl-directed reagents but was not inhibited by leupeptin or EDTA
- Non-reducing SDS-PAGE without boiling of the 300 kDa complex produced bands corresponding to the relative molecular masses of approximately 300, 150, 104, 88, 76 and 66 kDa.
- the 45, 27, 17, 15 kDa and one of the 44 kDa protein components of the 300 kDa complex are encoded by the gene the PrtR as presented schematically in FIG. 8 a.
- the complete nucleotide sequence and deduced amino acid sequence of the PrtR is shown in FIG. 8 b
- Each PrtR component is preceded by an arginyl or lysyl residue ( FIG. 8 a, b ) indicating that the polyprotein is processed by trypsin-like proteolytic specificity.
- PrtR45, PrtR44, PrtR27, PrtR 17 and PrtR 15 which fit well with the predicted sizes from the deduced PrtR amino acid sequence (53 9, 44 8, 29 5, 17 5 and 14 3 kDa respectively).
- the 44 kDa protein, the PrtR44 has been disclosed by previous workers as a culture fluid hemagglutinin/adhesin (Pike et al., 1994)[J Biol Chem 269 406-41 1].
- the PrtR44 has homology with the other non-proteinase components of the multiprotein complex suggesting a similar role for the PrtR27, PrtR 17 and PrtR 15 in interacting with the protease and/or in hemagglutination or adhesion.
- the PrtR45 Arg-specific endopeptidase component of the PrtR complex has the same characteristics and N-terminal sequence as the 50 kDa Arg-specific proteinase identified in the culture supernatant of P. gingivalis H66 by Chen et al (1992)[J Biol Chem 267 18896-18901] designated Arg-gingipain.
- the other proteins of the 300 kDa complex, the 48 kDa Lys-specific proteinase, the other 44 kDa protein and the 39 kDa and 15 Da proteins are encoded by a single gene the prtK presented schematically in FIG. 9 a.
- the complete nucleotide sequence and deduced amino acid sequence of the PrtK is shown in FIG. 9 b.
- the prtK is similar to the prtR in that it encodes a putative leader sequence, a prosequence followed by the proteinase domain which is then followed by sequence-related adhesins that have high homology with the C-terminal adhesins of the prtR.
- PrtK48 has the same enzyme characteristics as the 48 kDa proteinase purified from the culture supernatant of P. gingivalis 33277 by Fujimura et al. (1993) [Infect Immun 55 716-720].
- the PrtK48 also has the same N-terminal sequence and enzyme characteristics as the 60 kDa Lys-specific endopeptidase previously purified from the culture fluid of P. gingivalis H66 by Pike et al (1994) [J Biol Chem 269 406-411 ] and designated Lys-gingipain.
- the PrtK39, PrtK 15 and PrtK44 are all sequence-related and have high homology with the PrtR hemagglutinins/adhesins particularly the 15 kDa protein which is identical in both gene products suggesting that these proteins also are hemagglutinin/adhesins.
- PrtR-PrtK complexes As the 300 kDa proteinase-adhesin complex and higher molecular mass forms are composed of proteins from the two genes, the prtR and prtK, we suggest that they be designated PrtR-PrtK complexes.
- the deduced molecular mass of the mature PrtR is 160 kDa ( FIG. 9 a, b ) and mature PrtK is 163 kDa ( FIG.
- the cell sonicate and the chromatographic fractions had minimal or no proteolytic activity in the absence of reducing agents thus ensuring minimal enzymic activity during the chromatographic purifications.
- the characterization of the 300 kDa cell-associated complex as being composed of processed domains of the two genes the prtR and prtK suggests that the secreted, mature PrtR and PrtK proteins associate and then are processed, perhaps autolytically.
- the identification of several of the domains of the PrtR and PrtK in the culture supernatant by independent groups is consistent with the proteolytic (autolytic) processing of these polyproteins.
- high M r material 0.6 ⁇ 2 ⁇ 10 6 Da
- PrtR-PrtK complexes may further associate to form larger cell-associated aggregates.
- the high amino acid sequence homology between the PrtR44, PrtK39, PrtK44, PrtR27, PrtR17 and the 15 kDa protein of both the PrtR and PrtK suggests that these adhesins are responsible for the non-covalent cohesive interactions between the components of the PrtR-PrtK complexes and between the complexes themselves in the larger aggregates.
- This example describes the purification of a novel cell associated complex of Arg-specific and Lys-specific proteinases and sequence-related adhesins encoded by the two genes, the prtR and prtK.
- P. ginigivalis W50 was grown anaerobically at 37° C. on lysed horse blood agar and in modified BM media containing 1 ⁇ g/ml hemin. Bacteria were maintained on lysed horse blood plates by routine passage ( ⁇ 10 passages) and used to inoculate batch cultures. Batch culture growth in Brain Heart Infusion medium was monitored at 650 nm using a spectrophotometer (295E, Perkin-Elmer). Culture purity was checked routinely by Gram stain, microscopic examination and by using a variety of biochemical tests. Stocks were maintained as lyophilised cultures A culture of P. gingivalis was grown to late logarithmic phase and the cells harvested by centrifugation (5,000 ⁇ g, 20 min, 4° C.).
- Chloroform was added to the cell pellet and after gentle mixing the suspension was left for 15 min at room temperature. Following chloroform treatment, 20 mM Tris-HCl pH 8 0 buffer containing 50 mM NaCl was added and gently mixed. This mixture was then centrifuged (100,000 ⁇ , 30 min, 4° C.) and the supernatant diafiltered through a 100,000 M r cut-off membrane (Amicon) with five volumes of distilled water. This purifies and inactivates by oxidation the 294-323 kDa PrtR-PrtK which is freeze dried and used as an immunogen. The PrtR-PrtK purified by diafiltration was composed of 48, 45, 44, 39, 27, 17 and 15 kDa components as shown by SDS-PAGE ( FIG. 10 ).
- Polyclonal antiserum to PrtR-PrtK was raised in a rabbit by immunizing with the O 2 -inactivated PrtR-PrtK subcutaneously.
- the rabbit was immunized at day 0 with 40 ⁇ g of protein in incomplete Freund's adjuvant, day 14 with 90 ⁇ g of protein in incomplete. Freund's adjuvant, and day 28 with 60 ⁇ g of protein in incomplete Freund's adjuvant. Immunizations were carried out using standard procedures. Polyclonal antisera having a high titre against P. gingivalis was obtained. If desired the antibodies directed specifically against P. gingivalis can be obtained using standard procedures.
- This embodiment of the present invention is to provide PrtR-PrtK protein to be used in as an immunogen in a prophylactic and/or therapeutic vaccine for active immunization to protect against or treat infections caused by P. gingivalis .
- an antigen of P. gingivalis comprising a bacterial protein should be immunogenic, and induce functional antibodies directed to one or more surface-exposed epitopes on intact bacteria, wherein the epitope(s) are conserved amongst strains of P. gingivalis.
- the protein was purified from P. gingivalis using the method described herein in Example 1.
- Mice were immunized with the purified inactivated PrtR-PrtK protein (25 ug) with adjuvant (20 ug of QS21) two times at four week intervals.
- the purified PrtR-PrtK was inactivated by air oxidation.
- Blood from the immunized mice was drawn 32 days after the last immunization and the immune sera was pooled. The pooled immune sera was assayed against whole bacteria ( P. gingivalis strain W50) by an enzyme linked immunosorbent assay (ELISA).
- ELISA enzyme linked immunosorbent assay
- PrtR-PrtK protein Additional evidence supporting the immunogenicity of the PrtR-PrtK protein comes from a study of the human immune response to the PrtR-PrtK of P. gingivalis in which 86% of 43 patients with adult periodontitis had specific IgG in their sera to the PrtR-PrtK.
- PrtR-PrtK Another illustration of a desirable vaccine antigen is the O 2 -inactivated PrtR-PrtK. It has been demonstrated that the cell surface PrtR-PrtK is the target of bactericidal antibody generated from immunization with the inactivated protein. Polyclonal antiserum to PrtR-PrtK was raised in a rabbit by immunizing with the inactivated PrtR-PrtK subcutaneously. A rabbit was immunized at day 0 with 40 ⁇ g of protein in incomplete Freund's adjuvant, day 14 with 90 ⁇ g of protein in incomplete Freund's adjuvant, and day 28 with 60 ⁇ g of protein in incomplete Freund's adjuvant.
- the resultant antiserum was tested for its bactericidal activity against strain W50 of P. gingivalis.
- the bacteria were grown to logarithmic phase in brain-heart infusion (BHI) broth.
- An aliquot of the bacterial culture was diluted to 5 ⁇ 10 4 colony forming units (CFU) per ml in 10% bovine serum albumin in a balanced salt solution.
- the bactericidal assay reaction contained bacteria, polyclonal antiserum to inactivated PrtR-PrtK protein, a complement source consisting of normal human serum which was absorbed with protein G to remove antibodies, and the balanced salt solution.
- PrtR-PrtK protein possesses properties desirable of a vaccine antigen
- pooled immune sera raised to strain W50 was shown to have cross-reactivity with heterologous strains.
- Bacteria from each culture were harvested by swabs and suspended in PBS to an optical absorbance of 1 0 at 600 nm. A microliter of each suspension was applied to a nitrocellulose membrane and allowed to dry. The membrane was incubated one hour at room temperature in a solution of 5% non-fat dry milk in PBS to block the residual binding sites of the membrane.
- the membrane was washed twice with PBS, and then immersed in the blocking solution containing the immune sera diluted to 1 1000.
- the membrane was incubated with the antibody overnight at 46° C. with gentle shaking.
- the membrane was washed three times with PBS and then incubated for 2 hours at room temperature with alkaline phosphatase conjugated recombinant protein G (1 1500 in PBS with 5% non-fat dry milk).
- the membrane was washed three times with PBS and bound antibody was detected by the addition of substrate.
- the immune sera reacted with all strains as strongly, or to a greater extent than, strain W50.
- the antibodies elicited by immunization of the PrtR-PrtK protein isolated from strain W50 cross-reacted with all heterologous strains tested.
- PrtR-PrtK may be purified from a host containing a recombinant vector which expresses PrtR-PrtK
- hosts include, but are not limited to, bacterial transformants, yeast transformants, filamentous fungal transformants, and cultured cells that have been either infected or transfected with a vector which encodes PrtR-PrtK.
- Many methods are known for the introduction of a vaccine formulation into the human or animal to be vaccinated. These include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, ocular, intranasal, and oral administration.
- the vaccine may further comprise a physiological carrier such as a solution, a polymer or liposomes, and an adjuvant, or a combination thereof.
- gingivalis W50 cells were prepared by incubating an aliquot of cells in 0 5% (vol/vol) of buffered formal saline overnight at 4° C.
- the chloroform extract of P. gingivalis was prepared as detailed in Example 2.
- Purification of PrtR-PrtK complex was performed as detailed in Example 1.
- the PrtR-PrtK domains were prepared by taking the PrtR-PrtK complex and incubating in the presence of 50 mM 2-mercaptoethanol for 8 h at 4° C. This resulted in the breakdown of the PrtR-PrtK complex to domains that were 15-115 kDa proteins as shown by gel filtration FPLC and SDS-PAGE as performed in Example 1.
- P. gingivalis cells were grown at 37° C. on lysed horse blood agar (HBA) plates until day 3 or 4 in an anaerobic chamber (Mark 3 Anaerobic Workstation, Don Whitley Scientific Limited; with an air mixture of 8% H 2 , 12% CO 2 , 80% N 2 ), then passaged into 20 ml of brain heart infusion broth (BHIB, Oxoid) supplemented with 0.5 g/L cysteine and lmg/L haemin for 24 hours in a standard incubator at 37° C.
- HBA horse blood agar
- mice were marked for identification, their backs and chests shaved to make measurement of lesions possible, then weighed prior to inoculation with the challenge dose at a single site in the middle of the back.
- a 0 1 ml dose was given representing a predicted challenge dose of 3 ⁇ 10° bacteria per mouse.
- the inoculum dose was confirmed by culturing various dilutions of the challenge dose on lysed HBA plates and examining the number of colonies 7 days later.
- mice were examined daily for the number and size of lesions on their body and their size estimated by measuring the approximate surface area in mm 2 involved.
- Previous experiments had shown that in unimmunized mice, lesions developed on the belly of the mice following inoculation of live bacteria into the back or side. Any distressed animals were culled. Observations were carried out over two weeks and a summary of one such experiment is summarised below in Table 6 In this experiment while a dose of 3 ⁇ 10 9 bacteria per mouse was the desired number of bacteria, after planting out of the inoculum it was calculated that each mouse actually receive a challenge dose of 3 17 ⁇ 10 9 live P. gingivalis bacteria strain W50.
- PrtR-PrtK complex group The only group of animals that had a number of animals (40%) that exhibited no visible lesions at all was the PrtR-PrtK complex group (Group 3). All other groups, including formalin killed cells (Group 1), had all animals exhibiting visible lesions indicating that the PrtR-PrtK complex was a better immunogen than formalin killed cells TABLE 6 Immunisation with the PrtR-PrtK complex can protect mice from challenge with P. gingivalis .
- Lesion size Group Mean maximum lesion ⁇ size mm 2 P* 1 30.2 ⁇ 28.4 l 0.0008 2 39.0 ⁇ 33.2 0.009 3 30.0 ⁇ 36.0 0.0028 4 88.3 ⁇ 32.2 NS 5 86.8 ⁇ 41.1 — 6 201.7 ⁇ 125.8 0.012 *probability calculated by Mann Whitney rank sum test comparing Group 5 with other groups l mean ⁇ SD
- P. gingivalis W50 was grown in modified BM medium supplemented with 1 ⁇ g/ml haemin in an atmosphere of 10% CO 2 , 10% H 2 and 80% N 2 at 37° C.
- Escherichia coli JM1 09 and Escherichia coli LE392 were grown in LB medium at 37° C.
- Escherichia coli strains harbouring pUC 18 plasmids were grown in LB medium supplemented with 100 ⁇ g/ml ampicillin at 37° C.
- Chromosomal DNA was isolated from P. gingivalis W50 as described by Smith et al, [Oral Microbiol Immunol. 4 47-51 (1989)] except that cells were pelleted from a 500 ml late-exponential culture.
- the genomic library was constructed from BamHI partially-digested W50 DNA which was partially-filled with dGTP and dATP and ligated into LambdaGEM®-12 XhoI half-site arms (Promega) and packaged using Packagene® (Promega).
- prtR gene characterisation The genomic library was screened using degenerate synthetic oligonucleotides derived from the N-terminal sequence information of the purified PrtR45.
- the oligonucleotide probes were based on the amino acid sequence YEGDIKD (SEQ ID NO:10) (antisense) and KDFVDWKNQ (SEQ ID NO:11) (sense) and were 5′ end-labelled using ⁇ 32 P ATP and T4 polynucleotide kinase Approximately 1.5 ⁇ IO 4 phage were screened by lifting onto Nylon membrane filters and hybridised with radiolabeled oligonucleotides overnight in hybridisation buffer 6 ⁇ SSC (SSC is 15 mM sodium citrate, 150 mM NaCl pH 8 0), 0.25% SDS, 5 ⁇ Denhardt's solution and 1OO ⁇ g/ml salmon sperm DNA at 44° C.
- SSC is 15 mM sodium citrate, 150 mM NaC
- prtK gene characterisation The 5′ portion of the gene encoding PrtK was isolated from the same genomic library described above. The genomic library was screened using a degenerate synthetic oligonucleotide derived from the N-terminal sequence information of the purified PrtK48. The oligonucleotide probes were sense to the amino acid sequence DVYTDHGD (SEQ ID NO:12) and radiolabelled as described above. Hybridisation and washing conditions were as described above except that the temperature was 48° C. and the filters were washed extensively in a solution of 3 ⁇ SSC containing 0.01% SDS (w/v) at 48° C.
- Lambda clone 12 with an insert size of approximately 15 kb was selected and digested with BamHI and a 3.3 kb fragment was ligated into plasmid Zfar ⁇ HI-BAP pUC 18 and Escherichia coli JM1 09 transformed with the recombinant plasmid as described previously. Due to an internal BamHI site within prtK, the 3 3 kb BamHI fragment contained the 5′ portion of prtK which constituted the end of the lambda 12 clone. Sequence characterisation of the 3 3kb BamHI fragment showed that the DNA sequence encoding PrtK48 contains an internal EcoRI site.
- a second oligonucleotide probe (lysur) specific to the sequence THIGAH (SEQ ID NO:13) which is found within the PrtK48 was generated to determine a suitable strategy for cloning the 3 ′ end of prtK.
- Southern blot analysis of genomic DNA indicated that a 7 5 kb EcoRI fragment contained the entire 3′ portion of prtK.
- a second genomic library was prepared EcoRI digested DNA fragments of 6-8 kb were purified from an agarose gel and subsequently ligated to EcoRI digested Lambda Zap H-calf intestinal phosphatase-treated vector (Stratagene).
- the genomic library enriched for 6-8 kb P. gingivalis EcoRI fragments was packaged using Gigapacklll Gold packaging extract (Stratagene) according to the manufacturer's instructions.
- the library was screened as described previously, using oligonucleotide lysur except that hybridisation temperatures were 42° C. and filters were washed to 3 ⁇ SSC containing 0 01% SDS (w/v) at 42° C.
- In vivo excision of the Lambda Zap II positive genomic clone was performed (Stratagene instruction manual) to excise the pbluescript phagemid which was subsequently sequenced to generate the sequence information corresponding to the 3′end of the prtK gene.
- ANGIS Australian National Genomic Information Service
Abstract
This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis and in particular a multimeric cell association protein complex comprising the PrtR and PrtK proteins. Accordingly the invention provides a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis. The complex comprises at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain, the complex having a molecular weight of greater than about 200 kDa. The invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis.
Description
- This application is a continuation of application Ser. No.10/229,066, filed Aug. 28, 2002, which is a continuation of application Ser. No. 09/066,330, filed Sep. 15, 1998, the entire content of which is hereby incorporated by reference in this application.
- This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis and in particular a multimeric cell associated protein complex comprising the PrtR and PrtK proteins. The invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis.
- Periodontal diseases are bacterial-associated inflammatory diseases of the supporting tissues of the teeth and range from the relatively mild form of gingivitis, the non-specific, reversible inflammation of gingival tissue to the more aggressive forms of periodontitis which are characterised by the destruction of the tooth's supporting structures. Periodontitis is associated with a subgingival infection of a consortium of specific Gram-negative bacteria that leads to the destruction of the periodontium and is a major public health problem. One bacterium that has attracted considerable interest is P. gingivalis as the recovery of this microorganism from adult periodontitis lesions can be up to 50% of the subgingival anaerobically cultivable flora, whereas P. gingivalis is rarely recovered, and then in low numbers, from healthy sites. A proportional increase in the level of P. gingivalis in subgingival plaque has been associated with an increased severity of periodontitis and eradication of the microorganism from the cultivable subgingival microbial population is accompanied by resolution of the disease. The progression of periodontitis lesions in non-human primates has been demonstrated with the subgingival implantation of P. gingivalis. These findings in both animals and humans suggest a major role for P. gingivalis in the development of adult periodontitis.
- P. gingivalis is a black-pigmented, anaerobic, asaccharolytic, proteolytic Gram-negative rod that obtains energy from the metabolism of specific amino acids. The microorganism has an absolute growth requirement for iron, preferentially in the form of haeme or its Fe(III) oxidation product haemin and when grown under conditions of excess haemin is highly virulent in experimental animals. A number of virulence factors have been implicated in the pathogenicity of P. gingivalis including the capsule, adhesins, cytotoxins and extracellular hydrolytic enzymes. In particular, proteases have received a great deal of attention for their ability to degrade a broad range of host proteins including structural proteins and others involved in defence. The proteins that have been shown to be substrates for P. gingivalis proteolytic activity include
collagen types 1 and IV, fibronectin, fibrinogen, laminin, complement and plasma clotting cascade proteins, αi-antitrypsin, αˆmacroglobulin, antichymotrypsin, antithrombin III, antiplasmin, cystatin C, IgG and IgA. The major proteolytic activities associated with this organism have been defined by substrate specificity and are “trypsin-like”, that is cleavage on the carboxyl side of arginyl and lysyl residues and collagenolytic although other minor activities have been reported. - P. gingivalis trypsin-like proteolytic activity has been shown to degrade complement, generating biologically active C5a, impair the phagocytic and other functions of neutrophils by modifying surface receptors, and abrogate the clotting potential of fibrinogen prolonging plasma clotting time. The trypsin-like proteolytic activity of P. gingivalis also generates Fc fragments from human IgGI stimulating the release of pro-inflammatory cytokines from mononuclear cells and is associated with vascular disruption and enhanced vascular permeation through the activation of the kallikrein-kinin cascade. P. gingivalis spontaneous mutants with reduced trypsin-like activity as well as wild-type cells treated with the trypsin-like protease inhibitor N-?-tosyl-L-lysine chloromethyl ketone are avirulent in animal models. Further, it has been shown that P. gingivalis grown under controlled, haemin-excess conditions expressed more trypsin-like and less collagenolytic activity and were more virulent in mice relative to cells grown under haemin-limited but otherwise identical conditions. The increased expression of the trypsin-like activity by the more virulent P. gingivalis has led to the speculation that the trypsin-like proteolytic activity may be the major determinant for infection or disease. However, the cell-associated trypsin-like proteolytic activities of P. gingivalis have not been characterised to date.
- There has been considerable endeavour to purify and characterise the trypsin-like proteases of P. gingivalis from cell-free culture fluids. Chen et al, (1992) [J Biol Chem 267 18896-18901] have purified and characterised a 50 kDa arginine-specific, thiol protease from the culture fluid of P. gingivalis H66 designated Arg-gingipain. A similar arginine-specific thiol protease has been disclosed in JP 07135973 and the amino acid sequence disclosed in WO 9507286 and in Kirszbaum et al, 1995 [Biochem Biophys Res Comm 207424-431 ]. Pike et al (1994) [J Biol Chem 269406-11] have characterised a 60 kDa lysine-specific cysteine proteinase from the culture fluid of P. gingivalis H66 designated Lys-gingipain and the partial gene sequence for this enzyme was disclosed in WO 9511298 and fully disclosed in WO 9617936. However, prior to the development of the present invention it was unknown that there existed on the cell surface of P. gingivalis a 300 kDa complex of arginine-specific and lysine-specific proteases both containing adhesin domains. The 300 kDa complex has been designated the PrtR-PrtK complex. The presence of the PrtR-PrtK cell surface complex exhibiting both arginine- and lysine-specific proteolytic activity together with adhesin activity was previously unknown. Furthermore, the new PrtR-PrtK complex of the present invention is expressed on the cell surface, is a major virulence-associated factor and contains unique epitopes not displayed on the individual domains. The previously disclosed arginine-specific and lysine-specific thiol proteases, as discussed, do not exhibit any of these features and have proven of limited application to date. However, the aforementioned features have rendered the PrtR-PrtK complex of the invention ideal for development of diagnostic and immunoprophylactic products. The PrtR-PrtK cell surface complex is accordingly of particular interest for diagnostics and neutralisation by passive immunity through oral compositions containing neutralising antibodies and by vaccine development. In particular for the development of an intra-oral recombinant bacterial vaccine, where the recombinant bacterium expressing an inactivated PrtR-PrtK is a genetically engineered commensal inhabitant of the oral cavity.
- Accordingly in a first aspect the present invention consists in a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis, the complex comprising at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain, the complex having a molecular weight of greater than about 200 kDa.
- In the context of this disclosure, the terms “adhesin” and “hemagglutinin” may be considered to be synonymous.
- In a preferred form of the present invention the multimeric protein complex is associated with virulent strains of Porphyronionas gingivalis, preferably has a molecular weight of about 294 to about 323 kDa and is preferably derived from P. gingivalis W50.
- It is also preferred that the multimeric protein complex is composed of 9 proteins These 9 proteins preferably have the following N-terminal sequences:
DVYTDHGDLYNTPVRML (SEQ ID NO:1) YTPVEEKQNGRMIVIVAKKYEGD (SEQ ID NO:2) SGQAEIVLEAHDVWNDGSGYQILLDADHDQYGQVIPS (SEQ ID NO:3) DTHFL PQSVWIERTVDLPAGTKYVAFR (SEQ ID NO:4) ANEAKVVLAADNVWGDNTGYQFLLDA (SEQ ID NO:5) ANEAKVVLAADNVWGDNTGYQFLLDA (SEQ ID NO:6) PQSVWIERTVDLPAGTKYVAFR (SEQ ID NO;7) ADFTETFESSTHGEAPAEWTTIDA (SEQ ID NO:8) ADFTETFESSTHGEAPAEWTTIDA (SEQ ID NO:9) - It is presently preferred that the 9 proteins are PrtK48, PrtR45, PrtR44, PrtK39, PrtK44, PrtR27, PrtR17,
PrtK 15 andPrtR 15 as described herein. - As the purified antigenic complex normally has enzymatic activity it is preferred in a number of uses the thiol endopeptidases are rendered inactive. This may be achieved in a number of ways, for example by oxidation or by mutation. It is presently preferred that the inactivation is by oxidation.
- In yet another preferred embodiment of the present invention the multimeric protein complex is encoded by the DNA sequence shown in
FIGS. 8B and 9B . - In a second aspect the present invention consists in a composition for use in eliciting an immune response directed against Porphyromonas gingivalis, the composition comprising an effective amount of the complex of the first aspect of the present invention and a suitable adjuvant and/or acceptable carrier.
- In a third aspect the present invention consists in an antibody preparation comprising antibodies specifically directed against the complex of the first aspect of the present invention. The antibodies may be polyclonal antibodies or monoclonal antibodies.
- In a fourth aspect the present invention consists in a method of treating a subject suffering from Porphyromonas gingivalis infection, the method comprising administering to the subject an amount of the antibody preparation of the third aspect of the present invention effective to at least partially neutralize the PrtR-PrtK complex of Porphyromonas gin givalis.
- As will be recognised by those skilled in the art the antibody preparation may be administered by any of a number of well known routes, however, it is presently preferred that the preparation is administered orally.
- In a fifth aspect the present invention consists in a method of reducing the prospect of P. gingivalis infection in an individual and/or severity of disease, the method comprising administering to the individual an amount of the composition of the second aspect of the present invention effective to induce an immune response in the individual directed against P. gingivalis.
- In yet a further aspect the present invention consists in a recombinant host cell, the host cell being transformed with a DNA sequence(s) encoding PrtR-PrtK operatively linked to control sequences such that under appropriate conditions the host cell expresses PrtR-PrtK.
- In another aspect, the present invention is directed to novel DNA sequences involving PrtR-PrtK constructs and vectors including plasmid DNA, and viral DNA such as human viruses, animal viruses, insect viruses, or bacteriophages which can be used to direct the expression of PrtR-PrtK protein in appropriate host cells from which the expressed protein may be purified. Another aspect of the present invention provides methods for molecular cloning of the genes encoding the PrtR-PrtK complex. The nucleic acid sequences of the present invention can be used in molecular diagnostic assays for P. gingivalis genetic material through nucleic acid hybridization, and including the synthesis of PrtR-PrtK sequence-specific oligonucleotides for use as primers and/or probes in amplifying, and detecting amplified, nucleic acids. Additionally, PrtR-PrtK complex can be used as an immunogen in prophylactic and/or therapeutic vaccine formulations against pathogenic strains of P. gingivalis, whether the immunogen is chemically synthesized, purified from P. gingivalis, or purified from a recombinant expression vector system. Alternatively, the genes encoding PrtR-PrtK may be incorporated into a bacterial or viral vaccine comprising recombinant bacteria or virus which is engineered to produce PrtR-PrtK by itself, or in combination with immunogenic epitopes of other pathogenic microorganisms. In addition, the genes encoding PrtR-PrtK operatively linked to one or more regulatory elements, can be introduced directly into humans to express the PrtR-PrtK to elicit a protective immune response. A vaccine can also be based upon a recombinant component of a mutated PrtR-PrtK incorporated into an appropriate vector and expressed in a suitable transformed host (eg. E. coli, Bacillus subtilis, Saccharoinyces cerevisiae, COS cells, CHO cells and HeLa cells) containing the vector. The vaccine can be based on an intra-oral recombinant bacterial vaccine, where the recombinant bacterium expressing an inactivated PrtR-PrtK is a commensal inhabitant of the oral cavity. Unlike whole P. gingivalis cells or other previously prepared antigens based on fimbriae or the capsule the PrtR-PrtK complex of the invention or component parts thereof are safe and effective antigens for the preparation of a vaccine for the prevention of P. g7//g7vα//.i-associated periodontal disease. The invention therefore provides a range of recombinant products based on the PrtR-PrtK complex.
- The invention also provides antibodies raised against the said PrtR-PrtK complex, herein called anti-PrtR-PrtK antibodies. The antibodies may be blended into oral compositions such as toothpaste, mouthwash, toothpowders and liquid dentifrices, mouthwashes, troches, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products and other foodstuffs.
- In another aspect the invention provides a method of diagnosis for the presence of P. gingivalis characterised by the use of any one or a combination of an antibody, antigen or nucleic acid probe as hereinbefore defined comprising the application of known techniques including for example, enzyme linked immunosorbent assay.
- The invention also provides diagnostic kits comprising antibodies, antigens and/or nucleic acid probes as hereinbefore defined.
-
FIG. 1 . Anion exchange FPLC of a P. gingivalis W50 sonicate. The sonicate in TC buffer containing 50 mM NaCl was applied to a Hiload XK 16/10 Q sepharose column and eluted using a linear gradient from 0-100% buffer B over 90 min at a flow rate of 2 0 ml min′1. Fractions (6 ml) were assayed for proteolytic and amidolytic activity using azocasein, Bz-L-Arg-/?NA and Z-L-Lys-/?NA The amidolytic activity of each 6 ml fraction with Bz-L-Arg-pNA is shown by the histogram. -
FIG. 2 . Gel filtration FPLC of the pooled and concentrated fractions from Q sepharose anion exchange FPLC containing proteolytic/amidolytic activity. Anion exchange fractions containing the major peak of proteolytic/amidolytic activity were pooled, equilibrated in TC buffer containing 150 mM NaCl, concentrated and divided into four aliquots and each then independently applied to a gel filtration column (Superose 12HR 10/30) and eluted using the same buffer at a flow rate of 0 3 ml min′1. Fractions (0.5 ml) were assayed for proteolytic and amidolytic activity. Bz-L-Arg-/?NA amidolytic activity is shown by the histogram. Vo and Vt indicate the void and total volumes of the column respectively. The elution volumes of the standard proteins thyroglobulin 667 kDa,catalase 232 kDa andaldolase 158 kDa are marked. -
FIG. 3 . SDS-PAGE (boiled/reduced conditions) of the 300 kDa peak from gel filtration (Superose 12HR 10/30) FPLC.Lane 1, Pharmacia molecular mass standards (Mr shown in kDa).Lane -
FIG. 4 . Specific cleavage sites (marked with arrows) of αSi-casein by the proteolytic/amidolytic peak from gel filtration FPLC corresponding to 300 kDa. The protein α,i-casein was cleaved on the carboxyl side of arginyl and lysyl residues only (SEQ ID NO:14). -
FIG. 5 . Arg-sepharose FPLC of the 300 kDa gel filtration peak exhibiting Arg- and Lys-specific proteolytic activity. Gel filtration fractions containing the major peak of proteolytic activity (300 kDa) were pooled and applied to an arginine-sepharose column (5 ml arginine-Sepharose 4B) and washed with TC buffer containing 50 mM NaCl at 0 1 ml min″1 until the baseline returned to zero. The column was then further washed with 500 mM NaCl and then re-equilibrated with TC buffer containing 50 mM NaC. The column was first eluted with 200 mM lysine in TC buffer containing 50 mM NaCl, followed by 750 mM lysine in the same buffer. The column was then re-equilibrated and eluted with 200 M arginine in the same buffer at a flow rate of 0 1 ml min′1. Peaks were collected and assayed for amidolytic and proteolytic activity. Bz-L-Arg-?NA amidolytic activity is shown by the histogram and the arrows indicate the start of each step gradient. -
FIG. 6 . SDS-PAGE (boiled/reduced conditions) of 200 mM lysine eluant from the Arg-sepharose FPLC.Lane 1, Pharmacia molecular mass standards (Mr shown in kDa)Lane -
FIG. 7 . SDS-PAGE (boiled/reduced conditions) of the 750 mM lysine and 200 mM arginine eluants from the arginine-Sepharose FPLC and the purified 45 kDa Arg-specific endopeptidase.Lane Lane Lane 3, purified 45 kDa Arg-specific endopeptidase.Lane 4, Pharmacia molecular mass standards (Mr shown in kDa). Coomassie blue stained gel. -
FIG. 8 a. Schematic representation of the prtR gene. The PrtR nascent polyprotein is composed of a leader sequence, a prosequence followed by the Arg-specific cysteine proteinase PrtR45 (SEQ ID NO:15), and the adhesins PrtR44 (SEQ ID NO:16), PrtR15 (SEQ ID NO:17), PrtR17 (SEQ ID NO:18) and PrtR27 (SEQ ID NO: 19) all preceded by an arginyl or lysyl residue. -
FIG. 8 b. Nucleotide sequence of prtR (SEQ ID NO:20 and encoded protein, SEQ ID NO:21). -
FIG. 9 a. Schematic representation of the prtK gene. The PrtK nascent polyprotein is composed of a leader sequence, a prosequence followed by the Lys-specific cysteine proteinase PrtK48 (SEQ ID NO:22), and the adhesins PrtK39 (SEQ ID NO:19), PrtK 15 (SEQ ID NO:17) and PrtK44 (SEQ ID NO: 18) all preceded by an arginyl or lysyl residue. -
FIG. 9 b. Nucleotide sequence of prtK (SEQ ID NO:23 and encoded protein, SEQ ID NO:24). -
FIG. 10 . SDS-PAGE of the PrtR-PrtK complex purified by diafiltration.Lane 1 shows molecular mass markers.Lane 2 shows components of the PrtR-PrtK purified by diafiltration. -
FIG. 11 . ELISA titration of sera from 5 mice immunized twice with the PrtR-PrtK complex emulsified in Freund's Incomplete Adjuvant. Test sera (TS 32-36) and pre-immune sera (PIS 32-36) were screened using P. gingivalis W50 sonicate as the adsorbed antigen. Primary antibody dilutions of 1/100, 1/500, 1/2500 and 1/12500 were used. Bound antibody was determined using horseradish peroxidase-conjugated goat anti-mouse antibody and 3,3′,5,5′tetramethylbenezidine. The reaction product was quantitated spectrophotometrically using a 450 nm interference filter in a plate reader and recorded as optical density (O D ) readings. - The invention will now be described in greater detail by reference to the methods used and applied in the development of the invention and by reference to particular examples which provide the best methods known of performing the invention.
- The intra-oral bacterium Porphyromonas gingivalis possesses on its cell surface major trypsin-like proteinases as a 294-323 kDa heterodimeric protein complex of Arg-specific and Lys-specific thiol endopeptidases with hemagglutinins (adhesins) herein designated the PrtR-PrtK complex. The PrtR-PrtK complex can be purified from P. gingivalis cells by ultrasonication or chloroform extraction followed by diafiltration or anion exchange and Lys-sepharose or Arg-sepharose chromatography. The purified PrtR-PrtK complex is then used to generate antibodies using standard techniques. The animals used for antibody generation can be rabbits, goats, chickens, sheep, horses, cows etc. When a high antibody titre against the PrtR-PrtK complex is detected by immunoassay the animals are bled or eggs or milk are collected and the serum prepared and/or antibody purified using standard techniques or monoclonal antibodies produced by fusing spleen cells with myeloma cells using standard techniques. The antibody (immunoglobulin fraction) may be separated from the culture or ascites fluid, serum, milk or egg by salting out, gel filtration, ion exchange and/or affinity chromatography, and the like, with salting out being preferred. In the salting out method the antiserum or the milk is saturated with ammonium sulphate to produce a precipitate, followed by dialyzing the precipitate against physiological saline to obtain the purified immunoglobulin fraction with the specific anti-(PrtR-PrtK). The preferred antibody is obtained from the equine antiserum and the bovine antiserum and milk. In this invention the antibody contained in the antiserum and milk obtained by immunising the animal with the inactivated PrtR-PrtK may be blended into the oral composition. In this case the antiserum and milk as well as the antibody separated and purified from the antiserum and milk may be used Each of these materials may be used alone or in combination of two or more. Antibodies against the PrtR-PrtK can be used in oral compositions such as toothpaste and mouthwash to neutralise the PrtR-PrtK and thus prevent disease. The anti-(PrtR-PrtK) antibodies can also be used for the early detection of P. gingivalis in subgingival plaque samples by a chairside Enzyme Linked Immunosorbent Assay (ELISA).
- For oral compositions it is preferred that the amount of the above antibodies administered is 00001-50 g kg/day and that the content of the above antibodies is 00002-10% by weight preferably 0002-5% by weight of the composition. The oral composition of this invention wliich contains the above-mentioned serum or milk antibody may be prepared and used in various forms applicable to the mouth such as dentifrice including toothpastes, toothpowders and liquid dentifrices, mouthwashes, troches, periodontal pocket irrigating devices, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products and other foodstuffs. The oral composition according to this invention may further include additional well known ingredients depending on the type and form of a particular oral composition.
- In certain highly preferred forms of the invention the oral composition may be substantially liquid in character, such as a mouthwash or rinse. In such a preparation the vehicle is typically a water-alcohol mixture desirably including a humectant as described below. Generally, the weight ratio of water to alcohol is in the range of from about 1 1 to about 20 1. The total amount of water-alcohol mixture in this type of preparation is typically in the range of from about 70 to about 99 9% by weight of the preparation. The alcohol is typically ethanol or isopropanol. Ethanol is preferred.
- The pH of such liquid and other preparations of the invention is generally in the range of from about 4 5 to about 9 and typically from about 5 5 to 8. The pH is preferably in the range of from about 6 to about 8 0, preferably 7 4. The pH can be controlled with acid (e g citric acid or benzoic acid) or base (e g sodium hydroxide) or buffered (as with sodium citrate, benzoate, carbonate, or bicarbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, etc).
- Other desirable forms of this invention, the oral composition may be substantially solid or pasty m character, such as toothpowder, a dental tablet or a dentifrice, that is a toothpaste (dental cream) or gel dentifrice. The vehicle of such solid or pasty oral preparations generally contains dentally acceptable polishing material. Examples of polishing materials are water-insoluble sodium metaphosphate, potassium metaphosphate, tricalcium phosphate, dihydrated calcium phosphate, anhydrous dicalcium phosphate, calcium pyrophosphate, magnesium orthophosphate, trimagnesium phosphate, calcium carbonate, hydrated alumina, calcined alumina, aluminium silicate, zirconium silicate, silica, bentonite, and mixtures thereof. Other suitable polishing material include the particulate thermosetting resins such as melamine-, phenolic, and urea-formaldehydes, and cross-linked polyepoxides and polyesters. Preferred polishing materials include crystalline silica having particle sized of up to about 5 microns, a mean particle size of up to about 1.1 microns, and a surface area of up to about 50,000 cm2/gm., silica gel or colloidal silica, and complex amorphous alkali metal aluminosilicate.
- When visually clear gels are employed, a polishing agent of colloidal silica, such as those sold under the trademark SYLOID as
Syloid 72 and Syloid 74 or under the trademark SANTOCEL as Santocel 100, alkali metal alumino-silicate complexes are particularly useful since they have refractive indices close to the refractive indices of gelling agent-liquid (including water and/or humectant) systems commonly used in dentifrices. - Many of the so-called “water insoluble” polishing materials are anionic in character and also include small amounts of soluble material. Thus, insoluble sodium metaphosphate may be formed in any suitable manner as illustrated by Thorpe's Dictionary of Applied Chemistry, Volume 9, 4th Edition, pp. 510-51 1. The forms of insoluble sodium metaphosphate known as Madrell's salt and Kurrol's salt are further examples of suitable materials. These metaphosphate salts exhibit only a minute solubility in water, and therefore are commonly referred to as insoluble metaphosphates (IMP). There is present therein a minor amount of soluble phosphate material as impurities, usually a few percent such as up to 4% by weight. The amount of soluble phosphate material, which is believed to include a soluble sodium trimetaphosphate in the case of insoluble metaphosphate, may be reduced or eliminated by washing with water if desired. The insoluble alkali metal metaphosphate is typically employed in powder form of a particle size such that no more than 1% of the material is larger than 37 microns.
- The polishing material is generally present in the solid or pasty compositions in weight concentrations of about 10% to about 99%. Preferably, it is present in amounts from about 10% to about 75% in toothpaste, and from about 70% to about 99% in toothpowder. In toothpastes, when the polishing material is silicious in nature, it is generally present in amount of about 10-30% by weight. Other polishing materials are typically present in amount of about 30-75% by weight.
- In a toothpaste, the liquid vehicle may comprise water and humectant typically in an amount ranging from about 10% to about 80% by weight of the preparation. Glycerine, propylene glycol, sorbitol and polypropylene glycol exemplify suitable humectants/carriers. Also advantageous are liquid mixtures of water, glycerine and sorbitol. In clear gels where the refractive index is an important consideration, about 2.5-30% w/w of water, 0 to about 70% w/w of glycerine and about 20-80% w/w of sorbitol are preferably employed. Toothpaste, creams and gels typically contain a natural or synthetic thickener or gelling agent in proportions of about 0.1 to about 10, preferably about 0.5 to about 5% w/w. A suitable thickener is synthetic hectorite, a synthetic colloidal magnesium alkali metal silicate complex clay available for example as Laponite (e.g. CP, SP 2002, D) marketed by Laporte Industries Limited. Laponite D is, approximately by weight 58.00% SiO2, 25.40% MgO, 3.05% Na2O, 0.98% Li2O, and some water and trace metals. Its true specific gravity is 2.53 and it has an apparent bulk density of 1.0 g/ml at 8% moisture.
- Other suitable thickeners include Irish moss, iota carrageenan, gum tragacanth, starch, polyvinylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutyl methyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose (e.g. available as Natrosol), sodium carboxymethyl cellulose, and colloidal silica such as finely ground Syloid (e.g. 244). Solubilizing agents may also be included such as humectant polyols such propylene glycol, dipropylene glycol and hexylene glycol, cellosolves such as methyl cellosolve and ethyl cellosolve, vegetable oils and waxes containing at least about 12 carbons in a straight chain such as olive oil, castor oil and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate.
- It will be understood that, as is conventional, the oral preparations are to be sold or otherwise distributed in suitable labelled packages. Thus, ajar of mouthrinse will have a label describing it, in substance, as a mouthrinse or mouthwash and having directions for its use, and a toothpaste, cream or gel will usually be in a collapsible tube, typically aluminium, lined lead or plastic, or other squeeze, pump or pressurised dispenser for metering out the contents, having a label describing it, in substance, as a toothpaste, gel or dental cream.
- Organic surface-active agents are used in the compositions of the present invention to achieve increased prophylactic action, assist in achieving thorough and complete dispersion of the active agent throughout the oral cavity, and render the instant compositions more cosmetically acceptable. The organic surface-active material is preferably anionic, nonionic or ampholytic in nature which does not denature the antibody of the invention, and it is preferred to employ as the surface-active agent a detersive material which imparts to the composition detersive and foaming properties while not denaturing the antibody Suitable examples of anionic surfactants are water-soluble salts of higher fatty acid monoglyceride monosulfates, such as the sodium salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids, higher alkyl sulfates such as sodium lauryl sulfate, alkyl aryl sulfonates such as sodium dodecyl benzene sulfonate, higher alkylsulfo-acetates, higher fatty acid esters of 1,2-dihydroxy propane sulfonate, and the substantially saturated higher aliphatic acyl amides of lower aliphatic amino carboxylic acid compounds, such as those having 12 to 16 carbons in the fatty acid, alkyl or acyl radicals, and the like. Examples of the last mentioned amides are N-lauroyl sarcosine, and the sodium, potassium, and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine which should be substantially free from soap or similar higher fatty acid material. The use of these sarconite compounds in the oral compositions of the present invention is particularly advantageous since these materials exhibit a prolonged marked effect in the inhibition of acid formation in the oral cavity due to carbohydrates breakdown in addition to exerting some reduction in the solubility of tooth enamel in acid solutions. Examples of water-soluble nonionic surfactants suitable for use with antibodies are condensation products of ethylene oxide with various reactive hydrogen-containing compounds reactive therewith having long hydrophobic chains (e.g. aliphatic chains of about 12 to 20 carbon atoms), which condensation products (“ethoxamers”) contain hydrophilic polyoxyethylene moieties, such as condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols (e.g sorbitan monostearate) and polypropyleneoxide (e.g. Pluronic materials).
- Surface active agent is typically present in amount of about 0. 1-5% by weight. It is noteworthy, that the surface active agent may assist in the dissolving of the antibody of the invention and thereby diminish the amount of solubilizing humectant needed.
- Various other materials may be incorporated in the oral preparations of this invention such as whitening agents, preservatives, silicones, chlorophyll compounds and/or ammoniated material such as urea, diammonium phosphate, and mixtures thereof. These adjuvants, where present, are incorporated in the preparations in amounts which do not substantially adversely affect the properties and characteristics desired.
- Any suitable flavouring or sweetening material may also be employed. Examples of suitable flavouring constituents are flavouring oils, e.g. oil of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, and orange, and methyl salicylate. Suitable sweetening agents include sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartine, AMP (aspartyl phenyl alanine, methyl ester), saccharine, and the like. Suitably, flavour and sweetening agents may each or together comprise from about 0 1% to 5% more of the preparation.
- In the preferred practice of this invention an oral composition according to this invention such as mouthwash or dentifrice containing the composition of the present invention is preferably applied regularly to the gums and teeth, such as every day or every second or third day or preferably from 1 to 3 times daily, at a pH of about 4 5 to about 9, generally about 5 5 to about 8, preferably about 6 to 8, for at least 2 weeks up to 8 weeks or more up to a lifetime.
- The compositions of this invention can be incorporated in lozenges, or in chewing gum or other products, e.g by stirring into a warm gum base or coating the outer surface of a gum base, illustrative of which may be mentioned jelutong, rubber latex, vinylite resins, etc, desirably with conventional plasticisers or softeners, sugar or other sweeteners or such as glucose, sorbitol and the like.
- The composition of this invention also includes targeted delivery vehicles such as periodontal pocket irrigation devices, collagen, elastin, or synthetic sponges, membranes or fibres placed in the periodontal pocket or used as a barrier membrane or applied directly to the tooth root.
- Another important form of the invention is a composition for use in eliciting an immune response directed against Porphyromonas gingivalis based on the PrtR-PrtK complex and suitable adjuvant delivered by nasal spray, orally or by injection to produce a specific immune response against the PrtR-PrtK complex thereby reducing colonisation of P. gingivalis and neutralising the PrtR-PrtK thereby preventing disease. Due to the potent enzymatic activity of the complex typically the complex will be inactivated. A vaccine can also be based upon a recombinant component of the PrtR-PrtK incorporated into an appropriate vector and expressed in a suitable transformed host (eg E. coli, Bacillus subtilis, Saccharomyces cerevisiae, COS cells, CHO cells and HeLa cells) containing the vector. Unlike whole P. gingivalis cells or other previously prepared antigens based on fimbriae or the capsule the PrtR-PrtK complex is a safe and effective antigens for the preparation of a composition for use in the prevention of P. gingivalis-associated periodontal disease. The PrtR-PrtK complex can be produced using recombinant DNA methods as illustrated herein, or can be synthesized chemically from the amino acid sequence disclosed in the present invention. Additionally, according to the present invention, the PrtR-PrtK complex may be used to generate antisera useful for passive immunization against periodontal disease and infections caused by P. gingivalis.
- Various adjuvants are used in conjunction with vaccine formulations. The adjuvants aid by modulating the immune response and in attaining a more durable and higher level of immunity using smaller amounts of vaccine antigen or fewer doses than if the vaccine antigen were administered alone. Examples of adjuvants include incomplete Freund's adjuvant (IF A), Adjuvant 65 (containing peanut oil, mannide monooleate and aluminium monostrearate), oil emulsions, Ribi adjuvant, the pluronic polyols, polyamines, Avridine, Quil A, saponin, MPL, QS-21, and mineral gels such as aluminium salts. Other examples include oil in water emulsions such as SAF-1, SAF-0, MF59, Seppic ISA720, and other particulate adjuvants such as ISCOMs and ISCOM matrix. An extensive but not exhaustive list of other examples of adjuvants are listed in Cox and Coulter 1992 [In Wong WK (ed) Animals parasite control titilising technology. Bocca Raton, CRC press, 1992, 49-112]. In addition to the adjuvant the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, buffers or diluents as appropriate. One or more doses of the vaccine containing adjuvant may be administered prophylactically to prevent periodontitis or therapeutically to treat already present periodontitis.
- In another preferred composition the preparation is combined with a mucosal adjuvant and administered via the oral route. Examples of mucosal adjuvants are cholera toxin and heat labile E. coli toxin, the non-toxic B subunits of these toxins, genetic mutants of these toxins which have a reduced toxicity. Other methods which may be utilised to deliver the PrtR-PrtK complex orally include incorporation of the protease into particles of biodegradable polymers (such as acrylates or polyesters) by microencapsulation to aid uptake of the microspheres from the gastrointestinal tract and to protect degradation of the proteins. Liposomes, ISCOMs, hydrogels are examples of other potential methods which may be further enhanced by the incorporation of targeting molecules such as LTB, CTB or lectins for delivery of the PrtR-PrtK complex to the mucosal immune system. In addition to the vaccine and the mucosal adjuvant or delivery system the vaccine may include conventional pharmaceutically acceptable carriers, excipients, fillers, coatings, dispersion media, antibacterial and antifungal agents, buffers or diluents as appropriate.
- Another mode of this embodiment provides for either a live recombinant viral vaccine, recombinant bacterial vaccine, recombinant attenuated bacterial vaccine, or an inactivated recombinant viral vaccine which is used to protect against infections caused by P. gingivalis. Vaccinia virus is the best known example, in the art, of an infectious virus that is engineered to express vaccine antigens derived from other organisms. The recombinant live vaccinia virus, which is attenuated or otherwise treated so that it does not cause disease by itself, is used to immunize the host. Subsequent replication of the recombinant virus within the host provides a continual stimulation of the immune system with the vaccine antigens such as PrtR-PrtK complex, thereby providing long lasting immunity.
- Other live vaccine vectors include adenovirus, cytomegalovirus, and preferably the poxviruses such as vaccinia (Paoletti and Panicali, U.S. Pat. No 4,603,112) and attenuated Salmonella strains (Stocker et al, U.S. Pat. Nos. 5,210,035, 4,837,151, and 4,735,801, and Curtiss e/fl/, 1988, Vaccine 6.155-160). Live vaccines are particularly advantageous because they continually stimulate the immune system which can confer substantially long-lasting immunity. When the immune response is protective against subsequent P. gingivalis infection, the live vaccine itself may be used in a preventive vaccine against P. gingivalis. In particular, the live vaccine can be based on a bacterium that is a commensal inhabitant of the oral cavity. This bacterium can be transformed with a vector carrying a recombinant inactivated PrtR-PrtK and then used to colonise the oral cavity, in particular the oral mucosa. Once colonised the oral mucosa, the expression of the recombinant protein will stimulate the mucosal associated lymphoid tissue to produce neutralising antibodies. For example, using molecular biological techniques the genes encoding the PrtR-PrtK may be inserted into the vaccinia virus genomic DNA at a site which allows for expression of epitopes but does not negatively affect the growth or replication of the vaccinia virus vector. The resultant recombinant virus can be used as the immunogen in a vaccine formulation. The same methods can be used to construct an inactivated recombinant viral vaccine formulation except that the recombinant virus is inactivated, such as by chemical means known in the art, prior to use as an immunogen and without substantially affecting the immunogenicity of the expressed immunogen.
- In another variation of this embodiment, genetic material is used directly as the vaccine formulation Nucleic acid (DNA or RNA) containing sequences encoding the PrtR-PrtK protein complex operatively linked to one or more regulatory elements can be introduced directly to vaccinate the individual (“direct gene transfer”) against pathogenic strains of P. gingivalis Direct gene transfer into a vaccinated individual, resulting in expression of the genetic material by the vaccinated individual's cells such as vascular endothelial cells as well as the tissue of the major organs, has been demonstrated by techniques in the art such as by injecting intravenously an expression plasmid cationic liposome complex (Zhu et al, 1993, Science 261 209-211 ). Other effective methods for delivering vector DNA into a target cell are known in the art. In one example, purified recombinant plasmid DNA containing viral genes has been used to inoculate (whether parentally, mucosally, or via gene-gun immunization) vaccines to induce a protective immune response (Fynan et al 1993, Proc Natl Acad Sci USA 90 11478-11482). In another example, cells removed from an individual can be transfected or electroporated by standard procedures known in the art, resulting in the introduction of the recombinant vector DNA into the target cell. Cells containing the recombinant vector DNA may then be selected for using methods known in the art such as via a selection marker expressed in the vector, and the selected cells may then be re-introduced into the individual to express the PrtR-PrtK complex.
- As an alternative to active immunization, immunization may be passive, i e immunization comprising administration of purified immunoglobulin containing antibody against PrtR-PrtK.
- The present invention further provides the nucleotide sequence of the genes encoding the PrtR-PrtK complex, as well as the amino acid sequence deduced from the isolated genes. According to one embodiment of the present invention, using recombinant DNA techniques the genes encoding the PrtR-PrtK complex are incorporated into an expression vector, and the recombinant vector is introduced into an appropriate host cell thereby directing the expression of these sequences in that particular host cell.
- The expression system, comprising the recombinant vector introduced into the host cell, can be used (a) to produce PrtR-PrtK complex which can be purified for use as an immunogen in vaccine formulations, (b) to produce PrtR-PrtK complex to be used as an antigen for diagnostic immunoassays or for generating P. gingivalis-specific antisera of therapeutic and/or diagnostic value, (c) or if the recombinant expression vector is a live virus such as vaccinia virus, the vector itself may be used as a live or inactivated vaccine preparation to be introduced into the host's cells for expression of PrtR-PrtK complex, (d) for introduction into live attenuated bacterial cells or genetically engineered commensal intra-oral bacteria which are used to express PrtR-PrtK complex to vaccinate individuals, (e) or for introduction directly into an individual to immunize against the encoded and expressed PrtR-PrtK complex In particular the recombinant bacterial vaccine can be based on a commensal inhabitant of the human oral cavity or animal if the vaccine is to prevent periodontal disease in animals. The recombinant bacterial vaccine expressing inactivated PrtR-PrtK can be used to colonise the oral cavity, supragingival or subgingival plaque. The intra-oral bacterium can be isolated from the patient with periodontitis and genetically engineered to express inactivated PrtR-PrtK complex. The production of the inactivated PrtR-PrtK within the oral cavity will not be toxic to the oral mucosal tissues. However, the inactivated PrtR-PrtK will stimulate the mucosal-associated lymphoid tissues (MALT) to produce specific antibody to neutralise the PrtR-PrtK of P. gingivalis.
- Successful expression of a protein or peptide requires that either the insert comprising the gene or gene fragment, or the vector itself, contain the necessary elements for transcription and translation which is compatible with, and recognized by the particular host system used for expression. A variety of host systems may be utilized to express the PrtR-PrtK, which include, but are not limited to bacteria transformed with a bacteriophage vector, plasmid vector, or cosmid DNA; yeast containing yeast vectors; fungi containing fungal vectors, insect cell lines infected with virus (e.g baculovirus); and mammalian cell lines transfected with plasmid or viral expression vectors, or infected with recombinant virus (e.g vaccinia virus, adenovirus, adeno-associated virus, retrovirus, etc).
- Using methods known in the art of molecular biology various promoters and enhancers can be incorporated into the vector or the DNA sequence encoding PrtR-PrtK to increase the expression of the PrtR-PrtK amino acid sequences, provided that the increased expression of the amino acid sequences is compatible with (for example, non-toxic to) the particular host cell system used. Further, the DNA can be fused to DNA encoding other antigens, such as other bacterial outer membrane proteins, or other bacterial, fungal, parasitic, or viral antigens to create a genetically fused (sharing a common peptide backbone) multivalent antigen for use as an improved vaccine composition.
- The selection of the promoter will depend on the expression system used. Promoters vary in strength, i.e. ability to facilitate transcription. Generally, for the purpose of expressing a cloned gene, it is desirable to use a strong promoter in order to obtain a high level of transcription of the gene and expression into gene product. For example, bacterial, phage, or plasmid promoters known in the art from which a high level of transcription have been observed in a host cell system comprising E. coli include the lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the PR and PL promoters, lacUV5, ompF, bla, 1 pp, and the like, may be used to provide transcription of the inserted DNA sequence encoding PrtR-PrtK.
- Additional, if PrtR-PrtK protein may be lethal or detrimental to the host cells, the host cell strain/line and expression vectors may be chosen such that the action of the promoter is inhibited until specifically induced. For example, in certain operons the addition of specific inducers is necessary for efficient transcription of the inserted DNA (e g, the lac operon is induced by the addition of lactose or isopropylthio-beta-D-galactoside). A variety of operons such as the trp operon, are under different control mechanisms The trp operon is induced when tryptophan is absent in the growth media. The P promoter can be induced by an increase in temperature of host cells containing a temperature sensitive lambda repressor. In this way, greater than 95% of the promoter-directed transcription may be inhibited in uninduced cells. Thus, expression of recombinant PrtR-PrtK protein may be controlled by,culturing transformed or transfected cells under conditions such that the promoter controlling the expression from the inserted DNA encoding PrtR-PrtK amino acid sequences is not induced, and when the cells reach a suitable density in the growth medium, the promoter can be induced for expression from the inserted DNA.
- Other control elements for efficient gene transcription or message translation include enchancers, and regulatory signals. Enhancer sequences are DNA elements that appear to increase transcriptional efficiency in a manner relatively independent of their position and orientation with respect to a nearby gene. Thus, depending on the host cell expression vector system used, an enhancer may be placed either upstream or downstream from the inserted DNA sequences encoding PrtR-PrtK amino acid sequences to increase transcriptional efficiency. These or other regulatory sites, such as transcription or translation initiation signals, can be used to regulate the expression of the gene encoding PrtR-PrtK. Such regulatory elements may be inserted into DNA sequences encoding PrtR-PrtK amino acid sequences or nearby vector DNA sequences using recombinant DNA methods described herein for insertion of DNA sequences.
- Accordingly, P. gingivalis nucleotide sequences containing regions encoding for PrtR-PrtK, can be ligated into an expression vector at a specific site in relation to the vector's promoter, control, and regulatory elements so that when the recombinant vector is introduced into the host cell the P. gingivalis-specific DNA sequences can be expressed in the host cell. For example, the PrtR-PrtK specific DNA sequences containing their own regulatory elements can be ligated into an expression vector in a relation or orientation to the vector promoter and control elements which will allow for co-expression of the PrtR and PrtK. The recombinant vector is then introduced into the appropriate host cells, and the host cells are selected, and screened for those cells containing the recombinant vector. Selection and screening may be accomplished by methods known in the art including detecting the expression of a marker gene (e.g, drug resistance marker) present in the plasmid, immunoscreening for production of PrtR-PrtK specific epitopes using antisera generated to PrtR-PrtK specific epitopes, and probing the DNA of the host's cells for PrtR-PrtK specific nucleotide sequence using one or more oligonucleotides and methods described herein.
- Genetic engineering techniques may also be used to characterize, modify and/or adapt the encoded PrtR-PrtK protein. For example, site-directed mutagenesis to inactivate the protease domains of the PrtR-PrtK and to modify the protein in regions outside the protective domains, may be desirable to increase the safety and solubility.
- In particular the host organism for the vector containing the PrtR-PrtK genes and constructs can be a commensal inhabitant of the oral cavity; for example an inhabitant of subgingival plaque, supragingival plaque or a bacterium associated with the oral mucosa Examples of commensal intra-oral bacteria would be Streptococcus species and Actinomyces species, eg Streptococcus salivarius, Streptococcus sanguis, Actinomyces naeslundii. These organisms can be isolated from the periodontitis patient and then genetically engineered to express the inactivated PrtR-PrtK. The DNA encoding the PrtR-PrtK could be linked with DNA encoding leader sequences of extracellular proteins of these commensal intra-oral bacteria. The DNA encoding the PrtR-PrtK could also be linked with, or inserted into, the DNA encoding extracellular proteins to produce secreted fusion proteins. Examples of extracellular proteins that could be used to produce fusion proteins with the inactivated PrtR-PrtK could be the glucosyltranferases (GTF) or fructosyltransferases (FTF). The recombinant organism would be then re-introduced into the patients oral cavity and once colonised the oral mucosa or teeth would express the inactivated PrtR-PrtK to stimulate the mucosal associated lymphoid tissue to produce neutralising antibodies.
- Due to the conservation of the genes encoding PrtR-PrtK, the nucleic acid sequences of the present invention can be used in molecular diagnostic assays for detecting P. gingivalis genetic material. In particular, PrtR-PrtK sequence-specific oligonucleotides can be synthesized for use as primers and/or probes in amplifying, and detecting amplified, nucleic acids from P. gingivalis. Recent advances in molecular biology have provided several means for enzymaticaUy amplifying nucleic acid sequences. Currently the most commonly used method, PCR™ (polymerase chain reaction Cetus Corporation) involved the use of Taq Polymerase, known sequences as primers, and heating cycles which separate the replicating deoxyribonucleic acid (DNA) strands and exponentially amplify a gene of interest. Other amplification methods currently under development include LCR™ (ligase chain reaction, BioTechnica International) which utilizes DNA ligase, and a probe consisting of two halves of a DNA segment that is complementary to the sequence of the DNA to be amplified, enzyme QB replicase (Gene-Trak Systems) and a ribonucleic acid (RNA) sequence template attached to a probe complementary to the DNA to be copied which is used to make a DNA template for exponential production of complementary RNA, and NASBA™ (nucleic acid sequence-based amplification, Cangene Corporation) which can be performed on RNA or DNA as the nucleic acid sequence to be amplified.
- Nucleic acid probes that are capable of hybridization with specific gene sequences have been used successfully to detect specific pathogens in biological specimens at levels of sensitivity approaching 103-104 organisms per specimen (1990, Gene Probes for Bacteria, eds Macario and deMacario, Academic Press). Coupled with a method that allows for amplification of specific target DNA sequences, species-specific nucleic acid probes can greatly increase the level of sensitivity in detecting organisms in a clinical specimen. Use of these probes may allow direct detection without relying on prior culture and/or conventional biochemical identification techniques. This embodiment of the present invention is directed to primers which amplify species-specific sequences of the genes encoding PrtR-PrtK of P. gingivalis, and to probes which specifically hybridize with these amplified DNA fragments. By using the nucleic acid sequences of the present invention and according to the methods of the present invention, as few as one P. gingivalis organism may be detected in the presence of 10 ug/ml extraneous DNA.
- DNA may be extracted from clinical specimens which may contain P. gingivalis using methods known in the art. For example, cells contained in the specimen may be washed in TE buffer and pelleted by centrifugation. The cells then may be resuspended in 100 ul of amplification reaction buffer containing detergents and proteinase K Using the polymerase chain reaction, the resultant sample may be composed of the cells in 10 mM Tris pH 8 3, 50 mM KCl, 1 5mM MgCl2, 0 01% gelatin, 045% NP40™, 0 045
% Tween 20™, and 60 ug/ml proteinase K. The sample is incubated in a 55° C. water bath for l hour. Following the incubation, the sample is incubated at 95° C. for 10 minutes to heat-inactivate the proteinase K. The sample may then be amplified in accordance with standard PCR protocols. - The following examples are further illustrative of the nature of the present invention, but it is understood that the invention is not limited thereto. All amounts and proportions referred to herein are by weight unless otherwise indicated.
- (1) Preparation of Antigen.
- A. Anion Exchange and Affinity Chromatography
- P. gingivalis W50 was grown anaerobically at 37° C. on lysed horse blood agar and in modified BM media containing 1 μg/ml hemin Bacteria were maintained on lysed horse blood plates by routine passage (<10 passages) and used to inoculate batch cultures. Batch culture growth in Brain Heart Infusion medium was monitored at 650 nm using a spectrophotometer (295E, Perkin-Elmer). Culture purity was checked routinely by Gram stain, microscopic examination and by using a variety of biochemical tests. Stocks were maintained as lyophilised cultures. A culture of P. gingivalis was grown to late logarithmic phase and the cells harvested by centrifugation (5,000×g, 20 min, 4° C.) and then resuspended in 160 ml TC buffer (20 mM Tris-HCl pH 7 4 and 5 mM CaCl2) containing 50 mM NaCl and subjected to mild sonication using a Branson Sonifier 250 with an output control of 3 and a 50% duty cycle for 15 min at 4° C. The sonicate was centrifuged (100,000׈30 min, 4° C.) and the supernatant filtered (0.22 μm) prior to anion-exchange FPLC. The sonicate was applied to an anion-exchange column (Hiload XK 16/10 Q Sepharose, Pharmacia-LKB) cooled to 4° C., in multiple injections using a 50 ml superloop (Pharmacia-LKB). The sample was eluted using a linear gradient from 0-100% buffer B over 90 min at a flow rate of 2 0 ml min″1. The eluant was monitored at 280 nm and collected in 6 ml fractions using a Frac 100 fraction collector (Pharmacia-LKB). Buffer A was TC buffer containing 50 mM NaCl and buffer B was TC buffer containing 500 mM NaCl. Fractions were analysed for proteolytic and amidolytic activity using azocasein (A-2765, Sigma Chemical Co St Louis, Mo.), benzoyl-L-Arg-?-nitroanilide (Bz-L-Arg-pNa, Sigma) and benzyloxycarbonyl-L-Lys-nitroanilide (Z-L-Lys-/pNa, Calbiochem, Melbourne, Australia) vide infra Anion-exchange fractions containing the majority of proteolytic/amidolytic activity were pooled, washed and then concentrated in TC buffer containing 150 mM NaCl using a
centricon 10 micro-concentrator (Amicon). The sample was then divided into four aliquots and each was independently applied to a gel filtration column (Superose 12,HR 10/30, Pharmacia-LKB) using TC buffer containing 150 mM NaCl at a flow rate of 0 3 ml min″1. The eluant was monitored at 280 nm and peaks collected using a Frac 100 fraction collector The Mτ values of eluant peaks were determined using molecular mass gel filtration standards (Pharmacia-LKB) The peak containing the majority of the proteolytic/amidolytic activity was concentrated using acentricon 10 micro-concentrator and then applied at a flow rate of 0 1 ml min″ to an Arg-sepharose column (5 ml arginine-Sepharose 4B beads,HR 5/5 column, Pharmacia-LKB) and the unbound material collected. The column was washed with 500 mM NaCl and re-equilibrated with TC buffer containing 50 mM NaCl The column was first eluted with 200 mM lysine-HCl pH 7.4 in TC buffer containing 50 mM NaCl at a flow rate of 0.1 ml min″1. This was followed by 750 mM lysine-HCl pH 7.4 in the same buffer. The column was then re-equilibrated with TC buffer containing 50 mM NaCl and then eluted with 200 mM arginine-HCl pH 7.4 in TC buffer containing 50 mM NaCl at a flow rate of 0.1 ml min″1 . The unbound material collected was then re-applied to the Arg-sepharose column and the elution steps repeated. This sequence was repeated until all proteolytic activity had bound to the column. The eluant was monitored at 280 nm and peaks collected using a Frac 100 fraction collector. The peaks eluted from the Arg-sepharose by 200 mM lysine and 200 mM arginine were equilibrated with TC buffer containing 50 mM NaCl and 1.0% octyl-β-D-glucopyranoside and then applied to a Mono Q (HR 5/5) anion-exchange column and eluted using a linear gradient of 0-100% buffer B at a flow rate of 1.0 ml min″1. Buffer A was TC buffer containing 50 mM NaCl and 0.1% octyl-β-D-glucopyranoside and buffer B was TC buffer containing 500 mM NaCl and 0.1% octyl-β-D-glucopyranoside. The eluant was monitored at 280 nm and eluant peaks collected using a Frac 100 fraction collector. - Azocasein, and z-L-lys-Na were used to routinely assay FPLC fractions for proteolytic and amidolytic activity. A sample of each fraction (20-200:1) was incubated at 37° C. with azocasein (5 mg/ml final concentration) in TC buffer pH 8.0 containing 150 mM NaCl and 10 mM cysteine. For azocasein the reaction was stopped by the addition of 30% trichloroacetic acid at 4° C. Samples were centrifuged and the wo of the supernatant measured using a spectrophotometer (Perkin Elmer, model 552).
- For the synthetic chromogenic substrates samples of each chromatographic fraction (5-50:1) were incubated at 37° C. with Bz-L-Arg-pNa or z-L-Lys-pNa (1.0 mM final concentration) in a total volume of 350:1 100 mM Tris-HCl pH 8.0 buffer containing 150 mM NaCl, 10 mM cysteine and 5 mM CaCl2. Inhibitors and activators were added to the purified enzymes in 100 mM Tris-HCl pH 8.0 buffer containing 150 mM NaCl. Absorbance was measured at 410 nm in a Hewlett Packard 8452 A Diode Array spectrophometer and the amidolytic activity expressed in U, where U=μmol substrate converted min″1 at 37° C. Trypsin (E C.3.4.21.4, T 8253 Sigma) was used as a standard. The protein concentration of FPLC fractions and purified samples was determined using the Bradford protein assay (Biorad) with BSA as a standard. A sample of the gel filtration chromatographic fraction (20 μl) exhibiting the major proteolytic and amidolytic activity was incubated for 4 h at 37° C. with 10 mg/ml of pure αSi-casein dissolved in TC buffer pH 8 0 containing 150 mM NaCl and 50 mM 2-mercaptoethanol. Following incubation the sample was equilibrated in 0 1% TFA (v/v) dissolved in Milli Q water (Buffer A). The sample was then applied to an HPLC reversed phase analytical column (C8, 7 μm, 4 6 mm×220 mm. Applied Biosystems Inc Brownlee Aquapore RP 300) and peptides eluted using a linear gradient from 0-100% buffer B over 40 min at a flow rate of 1 ml min″1 (140 A solvent delivery system). Buffer B was 80% acetonitrile (v/v) in 0 1% (v/v) TFA in Milli Q water. The eluant was monitored at 214 nm using a 1000S diode array detector (Applied Biosystems). Peaks were collected manually and peptides identified using a combination of amino acid composition and sequence analyses as described previously.
- SDS-PAGE was performed using a Mini protean II electrophoresis system (Biorad) with 12% (w/v), 1 mm separating gels, overlaid with 5% stacking gels (Laemmli, 1970) [Nature 277 680-685]. Two volumes of each sample were mixed with one volume of buffer [0 5 M Tris-HCl,
pH 6 8, 5% v/v 2-mercaptoethanol, 10 0% w/v SDS, 0 05% w/v bromophenol blue (75% v/v) and glycerol (25% v/v)] and heated to 100° C. for 4 min unless otherwise stated SDS-PAGE was performed at room temperature using a current of 30-50 mA and a potential difference of ≦200 V. For silver staining, gels were fixed in methanol/water/acetic acid (45/45/10, v/v/v), washed in Milli Q water, reduced with 5 μg/ml dithiothreitol and then washed in Milli Q water, all for 30 min periods. Gels were then stained for 20 min with 0 1% w/v AgNO3 and developed with 3% w/v sodium carbonate containing 0 1% v/v formaldehyde and development stopped with glacial acetic acid. For Coomassie blue staining, gels were fixed in 12% TCA and stained overnight using 0 1% (w/v) purified Coomassie brilliant blue G 250 in 2% (w/v) phosphoric acid, 6% (w/v) ammonium sulphate. Gels were destained with methanol/water/acetic acid (50/40/10, v/v/v). Proteins were transferred onto a PVDF membrane (Problott, Applied Biosystems Inc (ABI)) for sequence analysis using a transblot cell (Biorad) PVDF membrane was wetted in 100% methanol and soaked in transfer buffer (10 mM CAPS/10% methanol,pH 1 1 5). Transfer was performed using a potential difference of 60 V (300 mA) for 90 min. Membranes were briefly stained using 0 1% (w/v) Coomassie brilliant blue R 250 in methanol/water/acetic acid (5/5/1, v/v/v). Protein bands were excised, destained for 10-30 sec in 50% methanol and then the N-terminal sequence determined using a Hewlett Packard 10005 A protein sequencer or a modified AB1 471-02 A protein sequencer fitted with a blott cartridge. - The ultrasonication procedure was effective at releasing the cell-associated Arg- and Lys-specific proteolytic activity of P. gingivalis W50 and 15 min was required for maximal release of activity. The sonicate of P. gingivalis W50 cells contained 0 30 mg ml″1 protein and 2 6 and 2 3 μmol min−1 mg protein″1 activity with 1 0 mM Bz-L-Arg-pNA and z-L-Lys-pNA as substrate respectively at 37° C. The crude sonicate was subjected to Q-sepharose anion exchange FPLC and a representative chromatogram is presented in
FIG. 1 Proteolytic/amidolytic activity eluted as one major peak between 246-320 mM NaCl (FIG. 1 ) which was collected, concentrated using a centricon-10 (Amicon) and then applied to theSuperose 12 gel filtration column (FIG. 2 ) Molecular mass gel filtration standards were used to determine the of the peaks obtained and the major peak, which also exhibited the major proteolytic/amidolytic activity, corresponded to 300 kDa (FIG. 2 ) Proteolytic/amidolytic activity was also associated with the high molecular mass material (0 6→2 0×106 Da) eluted from the gel filtration column. The 300 kDa gel filtration peak contained seven bands at 48, 45, 44, 39, 27, 17 and 15 kDa on SDS-PAGE analysis (FIG. 3 ). The seven bands were transblotted and subjected to N-terminal sequence analysis (Table 1). This analysis revealed that the 44 kDa band contained two proteins and the N-terminal sequences of these two 44 kDa proteins were assigned after further purification The N-terminal sequence of one of the 44 kDa proteins was identical to that of the 1 7 kDa protein and the 39 kDa and 27 kDa proteins also had identical N-termini (Table 1).TABLE 1 N-terminal sequences of proteins in the 300 kDa complex separated by SDS-PAGE Band N-terminal sequence (kDa) 48* DVYTDHGDLYNTPVRML (SEQ ID NO:1) 45† YTPVEEKQNGRMIVIVAKKYEGD (SEQ ID NO:2) 44† SGQAEIVLEAHDVWNDGSGYQILLDADHDQYGQVIPSDTHFL (SEQ ID NO:3) 44* PQSVWIERTVDLPAGTKYVAFR (SEQ ID NO:4) 39* ANEAKVVLAADNVWGDNTGYQFLLDA (SEQ ID NO:5) 27† ANEAKVVLAADNVWGDNTGYQFLLDA (SEQ ID NO:6) 17† PQSVWIERTVDLPAGTKYVAFR (SEQ ID NO:7) 15*† ADFTETFESSTHGEAPAEWTTIDA (SEQ ID NO:8)
*Proteins eluted from Arg-sepharose by 200 mM lysine
†Proteins eluted from Arg-sepharose by 200 mM arginine.
- Repeated gel filtration analyses of the Q-sepharose purified material or crude sonicates indicated that the major proteolytic/amidolytic activity was associated with 5 a peak corresponding to 300 kDa and higher molecular mass (0.6→2×106 Da) material that when boiled in SDS and subjected to SDS-PAGE analysis contained the same seven bands at 48, 45, 44, 39, 27, 17 and 15 kDa (
FIG. 3 ). - The 300 kDa gel filtration protein complex was incubated with α,i-casein. The α,i-casein peptides released by the action of the proteolytic activity of the 300 kDa complex were purified by RP-HPLC and identified by amino acid composition and sequence analyses. The sites of α,i-casein cleavage by the material of the 300 kDa complex were the carboxyl side of arginyl and lysyl residues only (
FIG. 4 ). All arginyl and lysyl residues of α,i-casein were cleaved except the N-terminal Arg and the Lys residues flanking the Ser(P) cluster sequence, presumably due to the high negative charge density (FIG. 4 ). The 300 kDa complex was then applied to an Arg-sepharose column and washed with TC buffer containing 500 mM NaCl (FIG. 5 ). The Arg-sepharose was eluted first with 200 mM lysine in TC buffer (FIG. 5 ) which eluted a small amount of the 48 kDa, 44 kDa, 39 kDa and 15 kDa proteins of the 300 kDa complex as shown by SDS-PAGE (FIG. 6 and Table 1). N-terminal sequence analysis of these transblotted proteins revealed that only one of the 44 kDa proteins of the 300 kDa complex was eluted with 200 mM lysine (Table 1). This fraction eluted from Arg-sepharose with 200 mM lysine contained only Lys-specific proteolytic/amidolytic activity Next the Arg-sepharose column was eluted with 750 mM lysine (FIG. 5 ) which removed the majority of the protein bound as the undissociated 300 kDa complex containing all seven bands (eight proteins) as shown by SDS-PAGE analysis (FIG. 7 ) The 750 mM lysine eluant exhibited both Arg- and Lys-specific proteolytic/amidolytic activity characteristic of the 300 kDa complex. The Arg-sepharose column was then eluted with 200 mM arginine in TC buffer (FIG. 5 ) The 200 mM arginine eluant contained small amounts of the 45, 44, 27, 17 and 15 kDa proteins as shown by SDS-PAGE (FIG. 7 ). This fraction exhibited only Arg-specific proteolytic/amidolytic activity. N-terminal sequence analysis of these transblotted proteins eluted with 200 mM arginine revealed that only one of the 44 kDa proteins of the 300 kDa complex was eluted with 200 mM arginine and this 44 kDa protein was different to the 44 kDa protein eluted with 200 mM lysine (Table 1). - The proteins eluted from the Arg-sepharose column with 200 mM lysine and 200 mM arginine were washed, concentrated and equilibrated with TC buffer containing 50 mM NaCl and 1 0% octyl-β-D-glucopyranoside and applied independently to a Mono Q anion exchange column. Elution from the Mono Q column with a NaCi gradient associated the Arg-specific proteolytic activity with the 45 kDa protein with a 25 fold purification over the original crude sonicate (Table 2,
FIG. 7 ). The specificity of the 45 kDa proteinase for arginyl residues was confirmed by the enzyme cleaving Bz-L-Arg-pNA but not z-L-Lys-pNA The Arg-specific 45 kDa enzyme was activated by thiols (particularly cysteine), not inhibited by PMSF or AEBSF but inhibited by sulphydryl-directed reagents, leupeptin and EDTA (Table 3). The inhibition by EDTA could be reversed by the addition of Ca2* (Table 3). The pH optimum of the enzyme was 7 5-8 0 and activity dropped off dramatically as the pH was lowered below 7 0 These results indicate that the 45 kDa enzyme is a calcium-stabilized, Arg-specific cysteine endopeptidase. The Lys-specific activity was characterized using the substrate Z-L-Lys-pNA and was associated with the 48 kDa protein purified from the 200 mM lysine eluant by Mono Q FPLC. The Lys-specific enzyme was also activated by thiols and inhibited by sulphydryl-directed reagents but was not inhibited by leupeptin or EDTA Non-reducing SDS-PAGE without boiling of the 300 kDa complex produced bands corresponding to the relative molecular masses of approximately 300, 150, 104, 88, 76 and 66 kDa.TABLE 2 Purification of the 45 kDa Arg-specific proteinase PrtR45 Proteolytic Specific Protein activity activity Purification Step (mg) (U*) U mg−1 fold Yield % Sonicate 48.0 124 2.6 1 100 Anion Exchange 8.2 64 7.8 3 52 FPLC (Q- sepharose) Gel filtration 3.9 46 11.8 5 37 FPLC (Superose 12) Affinity FPLC 0.7 17 24.3 9 14 (Arg-sepharose) Anion exchange 0.2 13 65.0 25 11 FPLC (mono Q)
*Amidolytic activity using 10 mM Bz-L-Arg-pNA, 1 unit = μmol min″1 at 37° C.
-
TABLE 3 Effects of various activators/inhibitors on the activity of the 45 kDa Arg-specific proteinase Concentration Activity Compound (mM) (%) 2-mercaptoethanol 1.0 100 10.0 158 50.0 189 Dithiothreithol 1.0 109 10.0 174 L-cysteine 0.1 183 1.0 320 10.0 487 PMSF*† 1.0 100 10.0 90 AEBSF*† 1.0 93 10.0 80 Iodoacetic acid† 1.0 82 10.0 19 PCMB*† 1.0 100 10.0 14 Leupeptin† 0.1 0 EDTA† 1.0 100 10.0 4 50.0 0 +Ca2+ 50.0 97 o-phenanthroline† 10.0 100
*PCMB, p-chloromercuribenzoic acid; PMSF, phenylmethyl sulfonyl fluoride, AEBSF, [4-(2-aminoethyl)-benzenesulfonylfluoride]
†These incubations also contained 10 mM 2-mercaptoethanol.
- The 45, 27, 17, 15 kDa and one of the 44 kDa protein components of the 300 kDa complex are encoded by the gene the PrtR as presented schematically in
FIG. 8 a. The complete nucleotide sequence and deduced amino acid sequence of the PrtR is shown inFIG. 8 b Each PrtR component is preceded by an arginyl or lysyl residue (FIG. 8 a, b) indicating that the polyprotein is processed by trypsin-like proteolytic specificity. We have designated these component parts of the 300 kDa complex, by their relative molecular masses as determined by SDS-PAGE, as the PrtR45, PrtR44, PrtR27,PrtR 17 andPrtR 15 which fit well with the predicted sizes from the deduced PrtR amino acid sequence (53 9, 44 8, 29 5, 17 5 and 14 3 kDa respectively). The 44 kDa protein, the PrtR44, has been disclosed by previous workers as a culture fluid hemagglutinin/adhesin (Pike et al., 1994)[J Biol Chem 269 406-41 1]. The PrtR44 has homology with the other non-proteinase components of the multiprotein complex suggesting a similar role for the PrtR27,PrtR 17 andPrtR 15 in interacting with the protease and/or in hemagglutination or adhesion. The PrtR45 Arg-specific endopeptidase component of the PrtR complex has the same characteristics and N-terminal sequence as the 50 kDa Arg-specific proteinase identified in the culture supernatant of P. gingivalis H66 by Chen et al (1992)[J Biol Chem 267 18896-18901] designated Arg-gingipain. - The other proteins of the 300 kDa complex, the 48 kDa Lys-specific proteinase, the other 44 kDa protein and the 39 kDa and 15 Da proteins are encoded by a single gene the prtK presented schematically in
FIG. 9 a. The complete nucleotide sequence and deduced amino acid sequence of the PrtK is shown inFIG. 9 b. The prtK is similar to the prtR in that it encodes a putative leader sequence, a prosequence followed by the proteinase domain which is then followed by sequence-related adhesins that have high homology with the C-terminal adhesins of the prtR. We have designated the 48 kDa Lys-specific proteinase the PrtK48 and its associated adhesins the PrtK39, PrtK15 and PrtK44 (FIG. 9 a, b) based on the sizes measured by SDS-PAGE which fit reasonably well with the predicted sizes from the deduced PrtK amino acid sequence (55 9, 44 8, 14 3 and 47 9 kDa respectively). The PrtK48 has the same enzyme characteristics as the 48 kDa proteinase purified from the culture supernatant of P. gingivalis 33277 by Fujimura et al. (1993) [Infect Immun 55 716-720]. The PrtK48 also has the same N-terminal sequence and enzyme characteristics as the 60 kDa Lys-specific endopeptidase previously purified from the culture fluid of P. gingivalis H66 by Pike et al (1994) [J Biol Chem 269 406-411 ] and designated Lys-gingipain. The PrtK39,PrtK 15 and PrtK44 are all sequence-related and have high homology with the PrtR hemagglutinins/adhesins particularly the 15 kDa protein which is identical in both gene products suggesting that these proteins also are hemagglutinin/adhesins. - As the 300 kDa proteinase-adhesin complex and higher molecular mass forms are composed of proteins from the two genes, the prtR and prtK, we suggest that they be designated PrtR-PrtK complexes. The deduced molecular mass of the mature PrtR is 160 kDa (
FIG. 9 a, b) and mature PrtK is 163 kDa (FIG. 9 b) such that the mass of the PrtR-PrtK heterodimer would be 323 kDa which is in good agreement with the r determined by gel filtration and non-boiling SDS-PAGE SDS-PAGE of the sample after boiling produced the seven bands of 48, 45, 44, 39, 27, 17 and 15 kDa corresponding to the domains of the two gene products, the PrtR and PrtK. These domains were only seen when the sample was boiled, with or without reducing agent, suggesting that the domains remain tightly non-covalently associated after proteolytic processing. The cell sonicate and the chromatographic fractions had minimal or no proteolytic activity in the absence of reducing agents thus ensuring minimal enzymic activity during the chromatographic purifications. The characterization of the 300 kDa cell-associated complex as being composed of processed domains of the two genes the prtR and prtK suggests that the secreted, mature PrtR and PrtK proteins associate and then are processed, perhaps autolytically. The identification of several of the domains of the PrtR and PrtK in the culture supernatant by independent groups is consistent with the proteolytic (autolytic) processing of these polyproteins. - The relative molecular mass of the processed PrtR-PrtK complex is likely to be attributable to the composition of 1 PrtK48+1 PrtR45+1 PrtR44+1 PrtK39+1 PrtK44+1 PrtR27+1 PrtR17+1 PrtK15+1 PrtR15=294-323 kDa C-terminal truncation, that is the 300 kDa complex would contain the five domains of the prtR and the four domains of the prtR gene products (
FIGS. 8 and 9 ). As high Mr material (0.6→2×106 Da) on gel filtration (FIG. 2 ) was also composed of the seven PrtR-PrtK bands then this suggests that the 300 kDa PrtR-PrtK complexes may further associate to form larger cell-associated aggregates. The high amino acid sequence homology between the PrtR44, PrtK39, PrtK44, PrtR27, PrtR17 and the 15 kDa protein of both the PrtR and PrtK suggests that these adhesins are responsible for the non-covalent cohesive interactions between the components of the PrtR-PrtK complexes and between the complexes themselves in the larger aggregates. It is interesting to note that some dissociation of the 300 kDa PrtR-PrtK complex occurred during the affinity chromatography on Arg-sepharose, although the majority of the protein eluted as the undissociated complex with 750 mM lysine The partial dissociation of the complex on binding to substrate may be a mechanism by which the complex targets specific host macromolecules and cells releasing the proteinase/adhesin domains at the target site on binding. - This example describes the purification of a novel cell associated complex of Arg-specific and Lys-specific proteinases and sequence-related adhesins encoded by the two genes, the prtR and prtK.
- B. Ultrafiltration and Diafiltration
- P. ginigivalis W50 was grown anaerobically at 37° C. on lysed horse blood agar and in modified BM media containing 1 μg/ml hemin. Bacteria were maintained on lysed horse blood plates by routine passage (<10 passages) and used to inoculate batch cultures. Batch culture growth in Brain Heart Infusion medium was monitored at 650 nm using a spectrophotometer (295E, Perkin-Elmer). Culture purity was checked routinely by Gram stain, microscopic examination and by using a variety of biochemical tests. Stocks were maintained as lyophilised cultures A culture of P. gingivalis was grown to late logarithmic phase and the cells harvested by centrifugation (5,000×g, 20 min, 4° C.). Chloroform was added to the cell pellet and after gentle mixing the suspension was left for 15 min at room temperature. Following chloroform treatment, 20 mM Tris-HCl pH 8 0 buffer containing 50 mM NaCl was added and gently mixed. This mixture was then centrifuged (100,000×, 30 min, 4° C.) and the supernatant diafiltered through a 100,000 Mr cut-off membrane (Amicon) with five volumes of distilled water. This purifies and inactivates by oxidation the 294-323 kDa PrtR-PrtK which is freeze dried and used as an immunogen. The PrtR-PrtK purified by diafiltration was composed of 48, 45, 44, 39, 27, 17 and 15 kDa components as shown by SDS-PAGE (
FIG. 10 ). - (2) Preparation of Antibodies
- Polyclonal antiserum to PrtR-PrtK was raised in a rabbit by immunizing with the O2-inactivated PrtR-PrtK subcutaneously. The rabbit was immunized at
day 0 with 40 μg of protein in incomplete Freund's adjuvant,day 14 with 90 μg of protein in incomplete. Freund's adjuvant, and day 28 with 60 μg of protein in incomplete Freund's adjuvant. Immunizations were carried out using standard procedures. Polyclonal antisera having a high titre against P. gingivalis was obtained. If desired the antibodies directed specifically against P. gingivalis can be obtained using standard procedures. - Methods and compounds for vaccine formulations related to PrtR-PrtK.
- This embodiment of the present invention is to provide PrtR-PrtK protein to be used in as an immunogen in a prophylactic and/or therapeutic vaccine for active immunization to protect against or treat infections caused by P. gingivalis. For vaccine purposes, an antigen of P. gingivalis comprising a bacterial protein should be immunogenic, and induce functional antibodies directed to one or more surface-exposed epitopes on intact bacteria, wherein the epitope(s) are conserved amongst strains of P. gingivalis.
- In one illustration of the PrtR-PrtK protein having the properties desirable of a vaccine antigen, the protein was purified from P. gingivalis using the method described herein in Example 1. Mice were immunized with the purified inactivated PrtR-PrtK protein (25 ug) with adjuvant (20 ug of QS21) two times at four week intervals. The purified PrtR-PrtK was inactivated by air oxidation. Blood from the immunized mice was drawn 32 days after the last immunization and the immune sera was pooled. The pooled immune sera was assayed against whole bacteria (P. gingivalis strain W50) by an enzyme linked immunosorbent assay (ELISA). For the whole cell ELISA, overnight cultures of bacteria were harvested by a swab and suspended in PBS to an absorbance of 0 1 at 600 nm Aliquots (100 ul) of the bacterial suspension were added to the wells of a 96 well microtiter plate and dried overnight at room temperature. The plates were blocked with IOOMI of 0 1% (w/v) gelatin in PBS. This, and all remaining incubations, were for one hour at room temperature unless otherwise specified The blocking solution was removed and 100 u\ of the immune sera, diluted in PBS with 0 1% (w/v) gelatin, was added to the wells and incubated. After washing three times with PBS, the bound antibodies were detected by incubating with 100 w1 of alkaline phosphatase conjugated recombinant protein G (1 500 in PBS with 0 1% (w/v) gelatin). The plates were washed and colour development was facilitated by the addition of 100 Hi/well of p-nitrophenyl phosphate (2 mg/ml in diethanolamine). After 30 minutes, the reaction was stopped by adding 50 w1 of 3M NaOH. The absorbance was read at 492 nm using an ELISA reader. Endpoint titers were determined as the reciprocal of the dilution at which the absorbance was greater than that of the blank wells. The results demonstrated that immunization with inactivated PrtR-PrtK elicit antibodies which can bind to one or more surface-exposed epitopes on intact P. gingivalis.
- Additional evidence supporting the immunogenicity of the PrtR-PrtK protein comes from a study of the human immune response to the PrtR-PrtK of P. gingivalis in which 86% of 43 patients with adult periodontitis had specific IgG in their sera to the PrtR-PrtK.
- Another illustration of a desirable vaccine antigen is the O2-inactivated PrtR-PrtK. It has been demonstrated that the cell surface PrtR-PrtK is the target of bactericidal antibody generated from immunization with the inactivated protein. Polyclonal antiserum to PrtR-PrtK was raised in a rabbit by immunizing with the inactivated PrtR-PrtK subcutaneously. A rabbit was immunized at
day 0 with 40 μg of protein in incomplete Freund's adjuvant,day 14 with 90 μg of protein in incomplete Freund's adjuvant, and day 28 with 60 μg of protein in incomplete Freund's adjuvant. The resultant antiserum was tested for its bactericidal activity against strain W50 of P. gingivalis. The bacteria were grown to logarithmic phase in brain-heart infusion (BHI) broth. An aliquot of the bacterial culture was diluted to 5×104 colony forming units (CFU) per ml in 10% bovine serum albumin in a balanced salt solution. The bactericidal assay reaction contained bacteria, polyclonal antiserum to inactivated PrtR-PrtK protein, a complement source consisting of normal human serum which was absorbed with protein G to remove antibodies, and the balanced salt solution. All reagents were added to the reaction to yield a 250 μl volume Aliquots of 25 μl of the reaction were removed and plated in triplicate on BHI agar attimes TABLE 4 Bactericidal activity of anti-(PrtR-PrtK) antibody CFU at CFU at Percent Sample Antiserum Complement time 0 time 60killing 1 10 μl 22 μl 225 0 100% 2 10 μl 0 227 390 0% 3 0 22 μl 254 286 0% - In further illustrating that the PrtR-PrtK protein possesses properties desirable of a vaccine antigen, pooled immune sera raised to strain W50 was shown to have cross-reactivity with heterologous strains. The pooled immune sera, prepared against PrtR-PrtK protein as described above, was examined for cross-reactivity with nine P. gingivalis strains from diverse clinical and geographical sources. Bacteria from each culture were harvested by swabs and suspended in PBS to an optical absorbance of 1 0 at 600 nm. A microliter of each suspension was applied to a nitrocellulose membrane and allowed to dry. The membrane was incubated one hour at room temperature in a solution of 5% non-fat dry milk in PBS to block the residual binding sites of the membrane. The membrane was washed twice with PBS, and then immersed in the blocking solution containing the immune sera diluted to 1 1000. The membrane was incubated with the antibody overnight at 46° C. with gentle shaking. The membrane was washed three times with PBS and then incubated for 2 hours at room temperature with alkaline phosphatase conjugated recombinant protein G (1 1500 in PBS with 5% non-fat dry milk). The membrane was washed three times with PBS and bound antibody was detected by the addition of substrate. The immune sera reacted with all strains as strongly, or to a greater extent than, strain W50. Thus, the antibodies elicited by immunization of the PrtR-PrtK protein isolated from strain W50 cross-reacted with all heterologous strains tested.
- For vaccine development, PrtR-PrtK may be purified from a host containing a recombinant vector which expresses PrtR-PrtK Such hosts include, but are not limited to, bacterial transformants, yeast transformants, filamentous fungal transformants, and cultured cells that have been either infected or transfected with a vector which encodes PrtR-PrtK. Many methods are known for the introduction of a vaccine formulation into the human or animal to be vaccinated. These include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, ocular, intranasal, and oral administration. The vaccine may further comprise a physiological carrier such as a solution, a polymer or liposomes, and an adjuvant, or a combination thereof.
- Protective Efficacy of Immunisation with the PrtR-PrtK Complex in an Animal Model.
- Various preparations of purified P. gingivalis proteins were tested in the mouse abscess model. This model is loosely based on the methods described by Kesavalu et al (1992) [Infect
Immun 60 1455-1464]. A typical experiment is outlined below Briefly BALB/c mice were obtained from ARC (Perth, Australia) and were immunised subcutaneously in the scruff of the neck with the preparations and doses according to Table 5 before challenge with live P. gingivalis strain W50, which was given at 10 weeks of age. Mice were given 2 doses of vaccine at 4 and I weeks before challenge. Formalin killed P. gingivalis W50 cells were prepared by incubating an aliquot of cells in 0 5% (vol/vol) of buffered formal saline overnight at 4° C. The chloroform extract of P. gingivalis was prepared as detailed in Example 2. Purification of PrtR-PrtK complex was performed as detailed in Example 1. The PrtR-PrtK domains were prepared by taking the PrtR-PrtK complex and incubating in the presence of 50 mM 2-mercaptoethanol for 8 h at 4° C. This resulted in the breakdown of the PrtR-PrtK complex to domains that were 15-115 kDa proteins as shown by gel filtration FPLC and SDS-PAGE as performed in Example 1. - All preparations were emulsified with an equal volume of Freund's Incomplete Adjuvant (FIA, Sigma) prior to injection.
- Animals were bled before and 1 week after the immunisation schedule. Sera were screened by ELISA using a P. gingivalis sonicate (prepared as in Example 1) as the adsorbed antigen. The immunogenicity of the purified PrtR-PrtK complex is shown in
FIG. 11 .TABLE 5 Immunization schedule No. of Group Doses Treatment n 1 2 1 × 10° Formalin killed P. gingivalis 11 cells in FIA 12 2 Chloroform extracted P. gingivalis proteins 10 in FIA 3 2 Affinity purified P. gingivalis PrtR- PrtK 5 complex in FIA 4 2 PrtR-PrtK Domains in FIA 10 5 2 Tris-cysteine buffer in FIA 10 6 2 Tris- cysteine buffer 10
1FIA = Freunds incomplete adjuvant
- For the preparation of the bacterial challenge P. gingivalis cells were grown at 37° C. on lysed horse blood agar (HBA) plates until
day Mark 3 Anaerobic Workstation, Don Whitley Scientific Limited; with an air mixture of 8% H2, 12% CO2, 80% N2), then passaged into 20 ml of brain heart infusion broth (BHIB, Oxoid) supplemented with 0.5 g/L cysteine and lmg/L haemin for 24 hours in a standard incubator at 37° C. Finally, 3 ml of this culture was added to 400 ml of BHIB-cysteine media and incubated for approximately 15 hours in a standard incubator at 37° C., until the optical density at 650 nm reached 0.18. The cells were then pelleted by centrifugation at 10,000 g for 30 minutes using a JA10 rotor in a Beckman High Speed centrifuge and then resuspended to a final dilution of 3×10° cells per ml in BHIB-cysteine media according to previously established growth curves for the W50 strain used in these experiments. Mice were marked for identification, their backs and chests shaved to make measurement of lesions possible, then weighed prior to inoculation with the challenge dose at a single site in the middle of the back. A 0 1 ml dose was given representing a predicted challenge dose of 3×10° bacteria per mouse. The inoculum dose was confirmed by culturing various dilutions of the challenge dose on lysed HBA plates and examining the number of colonies 7 days later. - Following challenge mice were examined daily for the number and size of lesions on their body and their size estimated by measuring the approximate surface area in mm2 involved. Previous experiments had shown that in unimmunized mice, lesions developed on the belly of the mice following inoculation of live bacteria into the back or side. Any distressed animals were culled. Observations were carried out over two weeks and a summary of one such experiment is summarised below in Table 6 In this experiment while a dose of 3×109 bacteria per mouse was the desired number of bacteria, after planting out of the inoculum it was calculated that each mouse actually receive a challenge dose of 3 17×109 live P. gingivalis bacteria strain W50.
- When mice were immunised with the various P. gingivalis fractions significant reductions (p<0.05) were seen in the size of the lesions with whole formalin killed P. gingivalis strain W50 cells (Group 1), the chloroform extracted proteins (Group 2) and the Prt-PrtK complex (Group 3) when compared with the lesion size of the animals receiving FIA (Group 5) (Table 6). The PrtR-PrtK domains (Group 4) of the broken down PrtR-PrtK complex did not significantly reduce lesion size compared with the control (Group 5). These results clearly show that the complex works effectivity as an immunogen whereas the PrtR-PrtK domains (15-1 15 kDa proteins) do not. The only group of animals that had a number of animals (40%) that exhibited no visible lesions at all was the PrtR-PrtK complex group (Group 3). All other groups, including formalin killed cells (Group 1), had all animals exhibiting visible lesions indicating that the PrtR-PrtK complex was a better immunogen than formalin killed cells
TABLE 6 Immunisation with the PrtR-PrtK complex can protect mice from challenge with P. gingivalis. Lesion size Group Mean maximum lesion\size mm2 P* 1 30.2 ± 28.4l 0.0008 2 39.0 ± 33.2 0.009 3 30.0 ± 36.0 0.0028 4 88.3 ± 32.2 NS 5 86.8 ± 41.1 — 6 201.7 ± 125.8 0.012
*probability calculated by Mann Whitney rank sumtest comparing Group 5 with other groups
lmean ± SD
- Cloning and Sequence Analysis of the PrtR and PrtK Genes
- Bacterial Strains
- P. gingivalis W50 was grown in modified BM medium supplemented with 1 μg/ml haemin in an atmosphere of 10% CO2, 10% H2 and 80% N2 at 37° C. Escherichia coli JM1 09 and Escherichia coli LE392 were grown in LB medium at 37° C. Escherichia coli strains harbouring
pUC 18 plasmids were grown in LB medium supplemented with 100 μg/ml ampicillin at 37° C. - Genomic Library Construction
- Chromosomal DNA was isolated from P. gingivalis W50 as described by Smith et al, [Oral Microbiol Immunol. 4 47-51 (1989)] except that cells were pelleted from a 500 ml late-exponential culture. The genomic library was constructed from BamHI partially-digested W50 DNA which was partially-filled with dGTP and dATP and ligated into LambdaGEM®-12 XhoI half-site arms (Promega) and packaged using Packagene® (Promega).
- prtR gene characterisation: The genomic library was screened using degenerate synthetic oligonucleotides derived from the N-terminal sequence information of the purified PrtR45. The oligonucleotide probes were based on the amino acid sequence YEGDIKD (SEQ ID NO:10) (antisense) and KDFVDWKNQ (SEQ ID NO:11) (sense) and were 5′ end-labelled using γ32P ATP and T4 polynucleotide kinase Approximately 1.5×IO4 phage were screened by lifting onto Nylon membrane filters and hybridised with radiolabeled oligonucleotides overnight in
hybridisation buffer 6×SSC (SSC is 15 mM sodium citrate, 150 mM NaCl pH 8 0), 0.25% SDS, 5× Denhardt's solution and 1OO μg/ml salmon sperm DNA at 44° C. Filters were washed extensively in a solution of 5×SSC containing 0.01% SDS (w/v) at 44° C. Positively-hybridising plaques were purified. Standard protocols for end-labelling of oligonucleotides and screening procedures were essentially as described in Sambrook et al. (1989) [Molecular Cloning A Laboratory Manual, 2nd ed, Cold Spring Harbour Laboratory Press]. Lambda clone four with an insert size of approximately 15 kb was selected and this fragment contained the entire prtR gene. The 15 kb fragment was cut with appropriate restriction enzymes and the fragments generated subcloned into pUC18 Escherichia coli JM1 09 was transformed with the recombinant plasmids using electroporation. - prtK gene characterisation: The 5′ portion of the gene encoding PrtK was isolated from the same genomic library described above. The genomic library was screened using a degenerate synthetic oligonucleotide derived from the N-terminal sequence information of the purified PrtK48. The oligonucleotide probes were sense to the amino acid sequence DVYTDHGD (SEQ ID NO:12) and radiolabelled as described above. Hybridisation and washing conditions were as described above except that the temperature was 48° C. and the filters were washed extensively in a solution of 3×SSC containing 0.01% SDS (w/v) at 48°
C. Lambda clone 12 with an insert size of approximately 15 kb was selected and digested with BamHI and a 3.3 kb fragment was ligated into plasmid ZfarøHI-BAP pUC 18 and Escherichia coli JM1 09 transformed with the recombinant plasmid as described previously. Due to an internal BamHI site within prtK, the 3 3 kb BamHI fragment contained the 5′ portion of prtK which constituted the end of thelambda 12 clone. Sequence characterisation of the 3 3kb BamHI fragment showed that the DNA sequence encoding PrtK48 contains an internal EcoRI site. Subsequently, a second oligonucleotide probe (lysur) specific to the sequence THIGAH (SEQ ID NO:13) which is found within the PrtK48 was generated to determine a suitable strategy for cloning the 3 ′ end of prtK. Southern blot analysis of genomic DNA indicated that a 7 5 kb EcoRI fragment contained the entire 3′ portion of prtK. In order to characterise the 3′ end of theprtλT gene a second genomic library was prepared EcoRI digested DNA fragments of 6-8 kb were purified from an agarose gel and subsequently ligated to EcoRI digested Lambda Zap H-calf intestinal phosphatase-treated vector (Stratagene). The genomic library enriched for 6-8 kb P. gingivalis EcoRI fragments was packaged using Gigapacklll Gold packaging extract (Stratagene) according to the manufacturer's instructions. The library was screened as described previously, using oligonucleotide lysur except that hybridisation temperatures were 42° C. and filters were washed to 3×SSC containing 0 01% SDS (w/v) at 42° C. In vivo excision of the Lambda Zap II positive genomic clone was performed (Stratagene instruction manual) to excise the pbluescript phagemid which was subsequently sequenced to generate the sequence information corresponding to the 3′end of the prtK gene. - DNA Sequencing. Double-stranded plasmid template DNA prepared following the procedure of Li and Schweizer [
Focus 15 19-20 (1993)] was sequenced in both directions using DNA sequence-derived, synthetic oligonucleotides, following the di-deoxy termination method [Proc Natl Acad Sci U S A 74 5463-5467 (1977)], using theSequenase version 2 0 nucleotide sequencing kit purchased from United States Biochemicals. Nucleotide and protein sequence data were analysed using programme suites accessed by the Australian National Genomic Information Service (ANGIS). - The following is an example of a proposed toothpaste formulation containing anti-(PrtR-PrtK) antibodies.
Ingredient % w/w Dicalcium phosphate dihydrate 50.0 Glycerol 20.0 Sodium carboxymethyl cellulose 1.0 Sodium lauryl sulphate 1.5 Sodium lauroyl sarconisate 0.5 Flavour 1.0 Sodium saccharin 0.1 Chlorhexidine gluconate 0.01 Dextranase 0.01 Goat serum containing anti-(PrtR-PrtK) 0.2 Water balance - The following is an example of a proposed toothpaste formulation.
Ingredient % w/w Dicalcium phosphate dihydrate 50.0 Sorbitol 10.0 Glycerol 10.0 Sodium carboxymethyl cellulose 1.0 Sodium lauryl sulphate 1.5 Sodium lauroyl sarconisate 0.5 Flavour 1.0 Sodium saccharin 0.1 Sodium monofluorophosphate 0.3 Chlorhexidine gluconate 0.01 Dextranase 0.01 Bovine serum containing anti-(PrtR- 0.2 PrtK) Water balance - The following is an example of a proposed toothpaste formulation.
Ingredient % w/w Dicalcium phosphate dihydrate 50.0 Sorbitol 10.0 Glycerol 10.0 Sodium carboxymethyl cellulose 1.0 Lauroyl diethanolamide 1.0 Sucrose monolaurate 2.0 Flavour 1.0 Sodium saccharin 0.1 Sodium monofluorophosphate 0.3 Chlorhexidine gluconate 0.01 Dextranase 0.01 Bovine milk 1 g containing anti-(PrtR-PrtK) 0.1 Water balance - The following is an example of a proposed toothpaste formulation.
Ingredient % w/w Sorbitol 22.0 Irish moss 1.0 Sodium Hydroxide (50%) 1.0 Gantrez 19.0 Water (deionised) 2.69 Sodium Monofluorophosphate 0.76 Sodium saccharine 0.3 Pyrophosphate 2.0 Hydrated alumina 48.0 Flavour oil 0.95 anti-(PrtR-PrtK) mouse monoclonal 0.3 sodium lauryl sulphate 2.00 - The following is an example of a proposed liquid toothpaste formulation.
Ingredient % w/w Sodium polyacrylate 50.0 Sorbitol 10.0 Glycerol 20.0 Flavour 1.0 Sodium saccharin 0.1 Sodium monofluorophosphate 0.3 Chlorhexidine gluconate 0.01 Ethanol 3.0 Equine 1 g containing anti-(PrtR-PrtK) 0.2 Linolic acid 0.05 Water balance - The following is an example of a proposed mouthwash formulation.
Ingredient % w/w Ethanol 20.0 Flavour 1.0 Sodium saccharin 0.1 Sodium monofluorophosphate 0.3 Chlorhexidine gluconate 0.01 Lauroyl diethanolamide 0.3 Rabbit 1 g containing anti-(PrtR-PrtK) 0.2 Water balance - It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
Claims (10)
1-11. (canceled)
12. An antibody preparation comprising antibodies specifically directed against a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis, the complex comprising at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain, the complex having a molecular weight of greater than about 200 kDa.
13. An antibody preparation as claimed in claim 12 in which the antibodies are polyclonal antibodies.
14. An antibody preparation as claimed in claim 12 in which the antibodies are monoclonal antibodies.
15. A method of treating a subject suffering from Porphyromonas gingivalis infection, the method comprising administering to the subject an amount of the antibody preparation as claimed in claim 12 effective to at least partially neutralize the PrtR-PrtK complex of Porphyromonas gingivalis.
16. A method as claimed in claim 15 in which the antibody preparation is administered as a mouth wash or as a dentifrice.
17. A method of reducing the prospect of P. gingivalis infection in an individual and/or severity of disease, the method comprising administering to the individual an amount of the composition as claimed in claim 11 effective to induce an immune response in the individual directed against P. gingivalis.
18. A recombinant host cell, the host cell being transformed with a DNA sequence(s) encoding PrtR-PrtK operatively linked to control sequences such that under appropriate conditions the host cell expresses PrtR-PrtK.
19. A recombinant host cell as claimed in claim 18 in which the host cell is an oral commensal.
20. A recombinant host cell as claimed in claim 18 in which the host cell is transformed with the DNA sequences shown in FIG. 8 b and FIG. 9 b.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/654,512 US20070189982A1 (en) | 1995-10-30 | 2007-01-18 | Diagnostics and treatments of Periodontal disease |
US13/064,286 US20110213129A1 (en) | 1995-10-30 | 2011-03-16 | Diagnostics and treatments of periodontal disease |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN6275A AUPN627595A0 (en) | 1995-10-30 | 1995-10-30 | Diagnostics and treatments of periodontal disease |
AUPN6275 | 1995-10-30 | ||
PCT/AU1996/000673 WO1997016542A1 (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
US09/066,330 US6511666B1 (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
AUPCT/AU96/00673 | 1996-10-30 | ||
US10/229,066 US20030157637A1 (en) | 1998-09-15 | 2002-08-28 | Diagnostics and treatments of periodontal disease |
US11/654,512 US20070189982A1 (en) | 1995-10-30 | 2007-01-18 | Diagnostics and treatments of Periodontal disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/229,066 Continuation US20030157637A1 (en) | 1995-10-30 | 2002-08-28 | Diagnostics and treatments of periodontal disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/064,286 Continuation US20110213129A1 (en) | 1995-10-30 | 2011-03-16 | Diagnostics and treatments of periodontal disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070189982A1 true US20070189982A1 (en) | 2007-08-16 |
Family
ID=3790602
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/066,330 Expired - Lifetime US6511666B1 (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
US11/654,512 Abandoned US20070189982A1 (en) | 1995-10-30 | 2007-01-18 | Diagnostics and treatments of Periodontal disease |
US13/064,286 Abandoned US20110213129A1 (en) | 1995-10-30 | 2011-03-16 | Diagnostics and treatments of periodontal disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/066,330 Expired - Lifetime US6511666B1 (en) | 1995-10-30 | 1996-10-30 | Diagnostics and treatments of periodontal disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/064,286 Abandoned US20110213129A1 (en) | 1995-10-30 | 2011-03-16 | Diagnostics and treatments of periodontal disease |
Country Status (12)
Country | Link |
---|---|
US (3) | US6511666B1 (en) |
EP (1) | EP0858504B1 (en) |
JP (1) | JP4117026B2 (en) |
KR (1) | KR100286055B1 (en) |
AT (1) | ATE312909T1 (en) |
AU (2) | AUPN627595A0 (en) |
DE (1) | DE69635582T2 (en) |
DK (1) | DK0858504T3 (en) |
ES (1) | ES2255082T3 (en) |
NZ (1) | NZ320015A (en) |
WO (1) | WO1997016542A1 (en) |
ZA (1) | ZA969130B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100034908A1 (en) * | 1997-12-10 | 2010-02-11 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US8431688B2 (en) | 1997-04-30 | 2013-04-30 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of Periodontitis associated with Porphyromonas gingivalis |
US10851138B2 (en) | 2008-08-29 | 2020-12-01 | Oral Health Australia Pty Ltd | Methods of preparing P. gingivalis antibodies |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0735293U (en) * | 1993-12-10 | 1995-06-27 | 株式会社松島製作所 | Lighting equipment |
AUPN627595A0 (en) * | 1995-10-30 | 1995-11-23 | University Of Melbourne, The | Diagnostics and treatments of periodontal disease |
US20030157637A1 (en) * | 1998-09-15 | 2003-08-21 | The University Of Melbourne | Diagnostics and treatments of periodontal disease |
EP1037999A4 (en) * | 1997-12-10 | 2005-03-23 | Csl Ltd | Porphorymonas gingivalis polypeptides and nucleotides |
AUPP494798A0 (en) | 1998-07-29 | 1998-08-20 | Pacific Biolink Pty Limited | Protective protein formulation |
AUPP893999A0 (en) * | 1999-03-01 | 1999-03-25 | Csl Limited | Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis |
AUPQ485999A0 (en) * | 1999-12-24 | 2000-02-03 | Csl Limited | P. gingivalis antigenic composition |
AUPQ718200A0 (en) | 2000-04-28 | 2000-05-25 | Csl Limited | Porphyromonas gingivalis recombinant proteins and truncations |
SE0400191D0 (en) * | 2004-01-30 | 2004-01-30 | Tendera Ab | A test kit for detecting periodontal disease |
AU2005287884B2 (en) * | 2004-09-23 | 2010-12-02 | The University Of Melbourne | Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection |
EP1799705A4 (en) * | 2004-09-23 | 2008-11-05 | Univ Melbourne | Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
WO2007082181A2 (en) | 2006-01-10 | 2007-07-19 | Colgate-Palmolive Company | Methods of modulating cell surface receptors to prevent or reduce inflammation |
CA2652957A1 (en) | 2006-06-27 | 2008-01-03 | Oral Health Australia Pty Ltd. | Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease |
PL2175851T3 (en) * | 2007-07-12 | 2013-11-29 | Oral Health Australia Pty Ltd | Biofilm treatment |
NZ595378A (en) | 2007-07-12 | 2013-04-26 | Immunology treatment for biofilms | |
US8140041B2 (en) * | 2009-08-27 | 2012-03-20 | Mediatek Inc. | Tunable capacitive device with linearization technique employed therein |
MY162557A (en) | 2010-02-26 | 2017-06-15 | Oral Health Australia Pty Ltd | Treatment or prevention of infection |
WO2019075260A1 (en) * | 2017-10-12 | 2019-04-18 | Sutrovax, Inc. | Periodontitis vaccine and related compositions and method of use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5711937A (en) * | 1993-06-28 | 1998-01-27 | Lion Corporation | Oral composition |
US6511666B1 (en) * | 1995-10-30 | 2003-01-28 | The University Of Melbourne | Diagnostics and treatments of periodontal disease |
US7749502B2 (en) * | 1997-04-30 | 2010-07-06 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830710A (en) * | 1988-09-08 | 1998-11-03 | University Of Florida | Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease |
US5523390A (en) * | 1993-09-10 | 1996-06-04 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis arginine-specific proteinase |
US5475097A (en) * | 1993-10-21 | 1995-12-12 | University Of Georgia Research Foundation, Inc. | Lysine-specific Porphyromonas gingivalis proteinase |
EP0717747B1 (en) * | 1993-09-10 | 2003-06-04 | The University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis arginine-specific proteinase coding sequences |
-
1995
- 1995-10-30 AU AUPN6275A patent/AUPN627595A0/en not_active Abandoned
-
1996
- 1996-10-30 US US09/066,330 patent/US6511666B1/en not_active Expired - Lifetime
- 1996-10-30 NZ NZ320015A patent/NZ320015A/en not_active IP Right Cessation
- 1996-10-30 JP JP51691597A patent/JP4117026B2/en not_active Expired - Fee Related
- 1996-10-30 ES ES96934198T patent/ES2255082T3/en not_active Expired - Lifetime
- 1996-10-30 AT AT96934198T patent/ATE312909T1/en active
- 1996-10-30 EP EP96934198A patent/EP0858504B1/en not_active Expired - Lifetime
- 1996-10-30 DE DE69635582T patent/DE69635582T2/en not_active Expired - Lifetime
- 1996-10-30 ZA ZA969130A patent/ZA969130B/en unknown
- 1996-10-30 WO PCT/AU1996/000673 patent/WO1997016542A1/en active IP Right Grant
- 1996-10-30 DK DK96934198T patent/DK0858504T3/en active
- 1996-10-30 KR KR1019980703117A patent/KR100286055B1/en not_active IP Right Cessation
- 1996-10-30 AU AU72673/96A patent/AU715456B2/en not_active Ceased
-
2007
- 2007-01-18 US US11/654,512 patent/US20070189982A1/en not_active Abandoned
-
2011
- 2011-03-16 US US13/064,286 patent/US20110213129A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5711937A (en) * | 1993-06-28 | 1998-01-27 | Lion Corporation | Oral composition |
US6511666B1 (en) * | 1995-10-30 | 2003-01-28 | The University Of Melbourne | Diagnostics and treatments of periodontal disease |
US7749502B2 (en) * | 1997-04-30 | 2010-07-06 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8431688B2 (en) | 1997-04-30 | 2013-04-30 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of Periodontitis associated with Porphyromonas gingivalis |
US8841420B2 (en) | 1997-04-30 | 2014-09-23 | The University Of Melbourne | Synthetic peptide constructs for the diagnosis and treatment of periodontis associated with Porphyromonas gingivalis |
US20100034908A1 (en) * | 1997-12-10 | 2010-02-11 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US8129500B2 (en) | 1997-12-10 | 2012-03-06 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US8642731B2 (en) | 1997-12-10 | 2014-02-04 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US20140302083A1 (en) * | 1997-12-10 | 2014-10-09 | The University Of Melbourne | Porphyromonas gingivalis polypeptides and nucleotides |
US10851138B2 (en) | 2008-08-29 | 2020-12-01 | Oral Health Australia Pty Ltd | Methods of preparing P. gingivalis antibodies |
US11572391B2 (en) | 2008-08-29 | 2023-02-07 | Oral Health Australia Pty Ltd | Antibodies for prevention, treatment and diagnosis of P. gingivalis infection |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11406702B1 (en) | 2020-05-14 | 2022-08-09 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated Salmonella as a vaccine |
Also Published As
Publication number | Publication date |
---|---|
AUPN627595A0 (en) | 1995-11-23 |
EP0858504A1 (en) | 1998-08-19 |
WO1997016542A1 (en) | 1997-05-09 |
JP4117026B2 (en) | 2008-07-09 |
US6511666B1 (en) | 2003-01-28 |
DE69635582D1 (en) | 2006-01-19 |
EP0858504A4 (en) | 2002-12-04 |
ATE312909T1 (en) | 2005-12-15 |
ZA969130B (en) | 1997-06-24 |
EP0858504B1 (en) | 2005-12-14 |
ES2255082T3 (en) | 2006-06-16 |
KR19990067167A (en) | 1999-08-16 |
DE69635582T2 (en) | 2006-08-17 |
NZ320015A (en) | 1999-02-25 |
US20110213129A1 (en) | 2011-09-01 |
JP2000510817A (en) | 2000-08-22 |
DK0858504T3 (en) | 2006-02-13 |
AU7267396A (en) | 1997-05-22 |
AU715456B2 (en) | 2000-02-03 |
KR100286055B1 (en) | 2001-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070189982A1 (en) | Diagnostics and treatments of Periodontal disease | |
US8765144B2 (en) | Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection | |
US8784831B2 (en) | P. gingivalis antigenic composition | |
EP0954529B1 (en) | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis | |
US20030157637A1 (en) | Diagnostics and treatments of periodontal disease | |
CA2235224C (en) | Diagnostics and treatments of periodontal disease | |
AU2005287884B2 (en) | Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection | |
AU713844B2 (en) | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis | |
AU775228B2 (en) | P. gingivalis antigenic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |